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 I 
Summary 
 
 
Unfractionated heparin (UFH) and low-molecular-weight-heparin (LMWH) are the 
most common used clinical anticoagulants for treatment of patients with venous 
thromboembolism (VTE) or acute coronary syndrome (ACS) and for antithrombotic 
prophylaxis within hospitals. The clinical tendency increasingly favours LMWH,                
even intravenously, e.g. in ST elevation myocardial infarction (STEMI).  
 
To test the anticoagulant action of the heparins in the major part of the work,                       
the extrinsic coagulation activity assay (EXCA) was performed with 51 normal citrated 
plasmas or 213 patient plasmas (with normal PT and APTT in absence of LMWH) after 
50 µl sample supplementation with 0-1 IU/ml UFH or LMWH.                      
 
To test the procoagulant action of the heparins in the minor part of the work,                       
the recalcified coagulation activity assay (RECA) was performed with 10 normal 
citrated plasmas or 32 patient plasmas, after 50 µl sample supplementation with               
0-10 mIU/ml UFH or LMWH.  
 
1 IU/ml enoxaparin reduced the normal thrombin generation in EXCA to about 13 % of 
normal, whereas at 1 IU/ml heparin the normal thrombin generation was completely 
suppressed. This means that 1 IU/ml enoxaparin is a strongly therapeutic anticoagulant, 
whereas 1 IU/ml UFH is in the toxic range. 0.01 IU/ml heparin or enoxaparin reduced 
the normal thrombin generation in EXCA only by about 10 % or 20 %, respectively. 
 
Heparin at 0.1 mIU/ml does not reduce thrombin generation in RECA; instead it even 
increased the thrombin generation in RECA by about 20 %, whereas 0.1 mIU/ml 
enoxaparin significantly decreased the thrombin generation by about 30%-60%.               
This means that in ultra-low concentrations, as e.g. occurring in the end of heparin 
infusion, heparin might be dangerous especially for patients with susceptible intrinsic 
hemostasis.  It is suggested to add enoxaparin at the end of heparin infusion or to 
replace heparin by enoxaparin. 
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 II 
These results support the concept that the LMWH dosage of each individual patient 
should be adjusted with an ultra-specific thrombin generation assay as EXCA or INCA 
(intrinsic coagulation activity assay). The dosing of LMWH-enoxaparin must be 
individualized according to the patient´s need (prophylactic or therapeutic) and 
anticoagulant response as reflected by trigger-induced thrombin generation. Target for 
therapeutic or prophylactic anticoagulation is 10-20 % or 20-40 % of normal trigger-
induced thrombin generation, respectively. The adequate dosage of enoxaparin in the 
individual patient should be monitored by a specific thrombin generation assay. 
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III 
 
Zusammenfassung 
 
 
Unfraktioniertes Heparin (UFH) und niedermolekulares Heparin (NMH) sind die am 
häufigsten verwendeten klinischen Antikoagulantien zur Therapie von Patienten mit 
venösen Thromboembolien (VTE), akutem Koronarsyndrom (ACS) und für 
Thromboseprophylaxe in Krankenhäusern. Die klinische Tendenz favorisiert 
zunehmend NMH, auch intravenös, z.B. beim transmuralen Myokardinfarkt (STEMI). 
 
Der extrinsische Gerinnungs-Aktivitätstest (EXCA) wurde im Hauptteil der Arbeit bei 
51 normalen Citratplasmen oder 213 Citratplasmen der Patienten (bei normaler PT und 
APTT in Abwesenheit von NMH) nach 50 µl Supplementierung mit 0-1 IU/ml UFH 
oder NMH durchgeführt.  
 
Der recalcifizierte Gerinnungsaktivitätstest (RECA) wurde im Nebenteil der Arbeit mit 
10 normalen Citratplasmen und in 32 Citratplasmen der Patienten nach 50 µl 
Supplementierung mit 0-10 mIU/ml UFH oder NMH durchgeführt. 
 
1 IU/ml Enoxaparin reduzierte die normale Thrombin-Generierung in EXCA auf etwa 
13% der Norm, während bei 1 IU/ml Heparin die normale Thrombin-Generierung 
komplett supprimiert wurde. Dies bedeutet, dass 1 IU/ml Enoxaparin ein stark 
therapeutisches Antikoagulans ist, während 1 IU/ml UFH bereits im toxischen Bereich 
ist. 0.01 IU/ml Heparin oder Enoxaparin reduzierte die normale Thrombin-Generierung 
in EXCA nur um etwa 10% oder 20%. 
 
UFH bei 0.1 mIU/ml reduzierte die Thrombin-Generierung im RECA nicht, sondern 
erhöhte sogar die Thrombin-Generierung um etwa 20%, während 0.1 mIU/ml NMH 
signifikant die Thrombingenerierung um etwa 30% -60% hemmte. Dies bedeutet, dass 
Heparin in ultra-niedrigen Konzentrationen, wie z. B. am Ende der Heparin-Infusion, 
besonders für Patienten mit sensibler intrinsischer  Hämostase gefährlich werden  
könnte. Es wird vorgeschlagen, mit NMH das Ende der Heparin-Infusion zu 
überbrücken oder UFH auf NMH umzustellen.  
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IV 
 
Diese Ergebnisse unterstützen das Konzept, dass die Dosierung der NMHs für jeden 
Patienten individuell durch einen ultra-spezifischen Thrombin-Generierungstest       
(EXCA oder INCA (intrinsischer Gerinnungs-Aktivitätstest)) angepasst werden sollte. 
Die Dosierung der NMH soll individuell entsprechend dem Ziel der Antikoagulation 
(prophylaktisch oder therapeutisch) und dem plasmatischen Ansprechen auf das 
Heparin angepaßt werden. Zielaktivität für therapeutische oder prophylaktische 
Antikoagulation sind 10-20% oder 20-40% der normalen Trigger-induzierten 
Thrombin-Generierung respektiv. Die adäquate Dosierung des NMH beim 
individuellen Patienten sollte durch einen spezifischen Thrombin-Generierungstest 
kontrolliert werden. 
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V 
 
Abbreviations 
 
∆A/t      Absorption increase per time 
ACS Acute coronary syndrome 
ACT            Activated clotting time 
APLA        Antiphospholipid antibodies 
APTT         Activated partial thromboplastin time 
AT-3          Antithrombin-3 
BK             Bradykinin 
Ca2+ Calcium-Ions 
CRP           C - reactive protein 
CRT          Coagulation reaction time 
CTS          Chromogenic test system 
DIC           Disseminated intravascular coagulation 
EGF          Epidermal growth factor 
ER             Endoplasmic reticulum 
EXCA        Extrinsic coagulation activity assay 
FSP            Fibrin split products 
GAG          Glycosaminoglycan 
HC-2  Heparin cofactor-2 
HIO  Heparin induced osteopenia 
HISN   Heparin induced skin necrosis 
HIT  Heparin induced thrombocytopenia 
HMWK   High-molecular-weight kininogen 
HRG   Histidine-rich glycoprotein 
IC50  50 % inhibitory concentration 
INCA intrinsic coagulation activity assay 
INR   International normalized ratio 
ISI  International sensitivity index 
IU  International units 
IU/m2 International units per squared meter 
IU/mg International units per milligram 
IV  Intravenous 
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IVBT-CT  in vitro bleeding test closure time 
KCT   Kaolin clotting time 
kDa  Kilodalton 
LMWH   Low-molecular-weight heparin 
mIU  Milli-international unit  
mmol/l Millimol per liter 
MV Mean value 
NaCl Sodium chloride 
OAT   Oral anticoagulant therapy 
PAR1  Protease-activated receptor 1 
PCa   Activated protein C 
PdCA   Phospholipid-dependent coagulation assay 
PF4  platelet factor 4 
PK   Prekallikrein 
PL  Phospolipid 
PPP  Platelet-poor plasma 
PRP  Platelet-rich plasma 
PT   Prothrombin time 
PTr   Prothrombin time ratio 
RECA  Recalcified coagulation activity assay 
SC  Subcutaneous 
SD  Standard deviation 
SGAG   Sulphated glycosaminoglycans 
SHBG   Sex hormone-binding globulin 
TAFI   Thrombin-activated fibrinolysis inhibitor 
TF  Tissue factor 
TGT   Thrombin generation test 
TM   Thrombomodulin 
TSR   Thrombin-sensitive region 
TT   Thrombin time 
TVT   Taipan venom test 
UFH   Unfractionated heparin 
VKD   Vitamin K-dependent 
VTE   venous thromboembolism 
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vWF   von Willebrand factor 
WBA  Whole blood aggregometry 
WBCT  Whole blood clotting time 
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1. Introduction 
 
1.1. Physiology and Pathophysiology of Hemostasis 
 
1.1.1. Definition  
 
Hemostasis is the system of generation and destruction of micro- and macro-thrombi. 
Primary hemostasis is the thrombocytes system; secondary hemostasis the generation of 
plasmatic thrombin, tertiary hemostasis is cellular and plasmatic fibrinolysis.  
 
Hemostasis protects life by 
 
1. preventing critical minor bleeding or preventing major blood loss by 
thrombin-mediated sealing of injury sites in the vascular system, 
 
2. allowing vessel patency by inhibition of excess thrombin and plasmin-
mediated lysis of vessel lumen occluding thrombi. 
 
Hemostasis must be strictly controlled so that blood does not coagulate within the 
vasculature which would prevent normal blood flow. Blood flow may be lost because 
of pump failure, blood leakage, or blood vessel obstruction. According to the 
Virchow´s Law physiological hemostasis requires physiological  
a) blood flow,  
b) blood itself,  
c) blood vessels. 
 
Hemostasis consists of multiple processes that center on the generation of                         
α-thrombin, the enzyme that converts soluble fibrinogen into insoluble fibrin. 
Physiologically, unnecessary fibrin is removed by plasmin (Jenny NS, Mann KG. 
1998).  
 
There are two main triggers to initiate mammalian blood coagulation: the intrinsic 
trigger is an unphysiologic surface (e.g. cell fragments or a xenobiotic), the extrinsic 
trigger is tissue factor (TF, thromboplastin, CD142, coagulation factor III).  
Introduction                                        The Plasma Sensibility to Heparin and Enoxaparin 
______________________________________________________________________ 
 2 
Pathological amounts of TF in blood occur seldomly; only if an organ rich in TF such 
as brain or placenta is injured, the extrinsic pathway with its main protease F7a is 
activated.  
Most clinical situations are associated with an activation of the intrinsic pathway of 
blood coagulation, consisting of F12a, kallikrein, HMWK, F11a, F9a, F8a. The 
common pathway consists of F10a, F5a (accelerin), F2a (thrombin), fibrin. 
Phospholipids catalyze both intrinsic and extrinsic pathway, they are cofactors for F10a 
generation and F2a generation. Calcium ions are required to fold factors 2, 7, 9, and 10 
into an activatable form. The most important immediate regulator protein of blood 
coagulation is the polysulphated glycosaminoglycan (SGAG)-dependent antithrombin-
3 (AT-3). The Ca2+ dependent factors protein C and protein S act by subacute 
inactivation of F5a and F8a (Davidson CJ et al. 2003; Krem MM, Cera ED. 2002).  
 
1.1.2. History of Hemostasis (Blood Coagulation and Fibrinolysis) 
The transformation of fluid blood to a gel-like substance (clot) has been a topic of great 
interest to scientists, physicians, and philosophers since the days of Plato and Aristotle 
(Jewett B (ed.). 1892). However, it was not until the beginning of the 18th century that 
blood clotting (coagulation) was appreciated as a means to prevent blood loss from 
wounds (hemostasis) (Petit JL. 1731). As with other areas of science, the microscope 
played a pivotal role in the understanding of coagulation. In the mid-17th century, 
Marcello Malpighi separated the individual components of a blood clot into fibers, 
cells, and serum. The fibers were later found to be derived from a plasma precursor 
(fibrinogen) and given the name fibrin (Babington BG. 1830). Further developments in 
the mid-19th century included the recognition of an enzyme (later called thrombin) that 
was capable of coagulating fibrinogen (Buchanan A. 1845) (Figure 1). In the latter half 
of the 19th century, the scientific community began to appreciate that clotting activities 
of thrombin could not be a constituent of normal plasma (otherwise clotting would 
occur continuously and at random) (Schmidt A. Zur Blutlehre. Leipzig, Vogel, 1892). 
This concept was vital to our understanding of the complex “checks and balances” 
system of coagulation, wherein inactive precursors are activated precisely where and 
when they are needed. It also fostered the belief that blood contained many, if not all, of 
the necessary elements for intravascular coagulation (circulating predominantly in an 
inactive form).  
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This hypothesis served as the basis for the theory of intrinsic coagulation (Schmidt A. 
Zur Blutlehre. Leipzig, Vogel, 1892).  
 
 
Figure 1. History of Hemostaseology. 
 
Researchers showed that blood coagulated when it came into contact with a foreign 
surface and that some surfaces were more “thrombogenic” than others. This concept 
paved the way for an expanding knowledge of hereditary disorders of coagulation (Hay 
J. 1813). Developments in defining extrinsic coagulation followed the pioneering work 
of several investigators (De Blainville HMD. 1834; Howell WH. 1912; Mills CA. 1921; 
Thackrah CT. 1819), all of whom described blood coagulation following the infusion of 
tissue suspensions (later called tissue thromboplastin or tissue factor). A revised theory 
of extrinsic coagulation suggested that an exposed tissue surface (from a damaged 
blood vessel wall) was capable of stimulating blood clotting. Later discoveries included 
the direct contribution of calcium ions (Bordet J. 1921), phospholipids (Chargaff E, 
1944), and other essential components of the prothrombinase complex (factors 5a, 10a) 
(Hougie C, 1957) to blood coagulation (Figure 2). 
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Stenflo isolated bovine vitamin K-dependent protein C, which was named protein C 
because it was the third peak to elute from the DEAE column (Stenflo J. 1976).  
 
 
 
Figure 2. Waterfall or cascade model of hemostasis 
 
The “waterfall” or “cascade” model of coagulation, proposed almost simultaneously by 
MacFarlane (1964) and Davie and Ratnoff (1964), expanded the former theory of 
Morawitz (1904) and provided both a structural and biochemical framework for 
understanding coagulation. The contribution of platelets to the coagulation process can 
be traced back to the mid-19th century and the original work of Alfred Donne, who 
discovered platelets with the help of a newly developed microscope lens (achromatic 
lens) (Donne A. 1842). However, the clinical importance of platelets in normal 
hemostasis was not appreciated until the end of the 19th century, when Sir William 
Osler (1874) described platelet aggregation and Hayem (1882) cited the importance of 
platelet plugs in preventing blood loss after tissue injury. The development of electron 
microscopy made it clear that platelets adhered to damaged blood vessels (Marcus AJ. 
1969) and subsequently were “activated” through a variety of pharmacologic (e.g., 
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adenosine diphosphate, epinephrine, thrombin) or mechanical (e.g., shear stress) stimuli 
(Grette K. 1962; Spaet TH, 1964; Willis AL, 1974). The surface of the activated 
platelet accelerates coagulation.  
 
The inability of blood to fully coagulate following death was observed centuries ago, 
possibly as early as the days of Hippocrates. Pioneering work near the end of the 18th 
century described the process of fibrinolysis and a mechanism whereby a circulating 
precursor (plasminogen) generated (with the appropriate stimulus) an active enzyme 
(plasmin) capable of degrading clotted blood (Christensen LR, 1945; Hedin SG. 1904). 
The potential clinical ramifications of fibrinolysis and its application in treating 
thrombotic disorders began with the work of Gratia in 1921, who observed that clots 
could be dissolved by staphylococcal extracts. Tillet and Garner (Tillett WS, Garner 
RL. 1933) later reported that bacteria-free filtrates of β-hemolytic streptococci 
contained a substance (streptokinase) that was capable of dissolving blood clots. Soon 
thereafter, the work of Sherry et al. (1959) highlighted the potential use of fibrinolytics 
in humans. Plasminogen activators were found in many tissues of the body, including 
blood vessels themselves (MacFarlane RG, Pilling J. 1947; Williams JRB. 1951). Their 
physiology and pharmacology is important in human medicine (Figure 3). 
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Figure 3. Fibrinolysis. The fibrinolytic system consists of an inactive precursor 
(plasminogen) that is converted (by the physiologic activators urokinase or t-PA or by 
therapeutic activators) to the aggressive protease plasmin that preferably splits fibrin 
but also fibrinogen to the respective split products (FSP). 
 
 
1.1.3. Vitamin K-Dependent Proteins 
Vitamin K-dependent (VKD) proteins, synthesized in the liver, play a central role in 
blood coagulation through either procoagulant or anticoagulant mechanisms. The 
vitamin K-dependent protein family includes the zymogen procoagulant factors F7, F9, 
F10, and prothrombin (F2) and the anticoagulants protein C, protein S (Figure 4). 
Except protein S, these proteins in their active form are serine proteases related to the 
trypsin and chymotrypsin superfamily. Limited cleavage of peptides (only at specific 
sites) converts the vitamin K-dependent zymogens into their active serine protease 
forms. (Girolami A,2008; Stafford DW 2005; Nelsestuen GL, 2000). Vitamin K is 
essential for the biosynthesis of these clotting factors by participating in the cyclic 
oxidation and reduction of the enzyme that converts 9 to 13 amino-terminal glutamic 
acid residues to γ-carboxyglutamic acid residues (Gla) (Berkner KL: 2008; 
Oldenburg J,2008). This post-translational multi-Gla linkage adds 9-13 negative 
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charges to the F 2, 7, 9, 10, PC, PS molecules that enable them to interact with Ca2+ and 
a membrane surface (Schwalbe RA, 1989). Blocking formation of the Gla residues 
addition is the basis for “blood-thinning” anticoagulant therapy with Phenprocoumon 
(Marcumar), Coumadin (Warfarin) and Acenocoumarol (Sintrom) derivatives, which 
are chemically similar in structure to vitamin K. This Ca2+ biochemistry is also the basis 
for the anticoagulant activity of sodium citrate, a reversible Ca2+ chelator, used for 
clinical laboratory testing of clotting activity. VKD-proteins are composed of 10-13 
NH2-terminal Gla residues followed by either a kringle domain (K) in prothrombin or 
an epidermal growth factor (EGF) like-domain in F7, F9, F10, protein C, and protein S 
(Figure 4).  
 
 
 
Figure 4. Schematic presentation of the vitamin K-dependent proteins. 
TSR: thrombin-sensitive region; SHGB: sex hormone-binding globulin; EGF: 
epidermal growth factor; K: kringle domain; Gla: γ-carboxyglutamic acid residues. 
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Thrombin (F2a) is the key serine protease in hemostasis. It is the enzyme that creates 
the fibrin clot. With regard to procoagulation, F2a activates many of the proteins in the 
clotting cascade including fibrinogen, F5, F8, F11, F13 (Crawley, J.T.B., 2007). F2a 
also activates platelets and vascular endothelial cells (Bahou, W.F, 2002) and initiates 
cellular responses including production and secretion of cytokines, growth factors and 
cellular adhesion molecules (Davie, E.W, 2006; Crawley, J.T.B., 2007). With regard to 
its anticoagulant function, thrombin activates anti-fibrinolytic components such as 
protein C and a fibrinolysis inhibitor (TAFI) (Wolberg, A.S. 2007). Thrombin’s 
precursor, prepro-prothrombin (Figure 5), is synthesized in hepatocytes where it 
undergoes posttranslational modifications. After entering the endoplasmic reticulum 
(ER), the signal peptide is removed and 10 glutamate residues adjacent to the 
propeptide are converted to γ-carboxyglutamate (Gla) residues (Stenflo, J., 1974; 
Nelsestuen, G.L., 1974; Wu, S.M., 1991). This Gla domain interacts with calcium ions 
and is critical for creating the conformation required to bind to negatively-charged 
phospholipid surfaces of injured vascular tissue and activated platelets which 
concentrates F9, F7, F10, and F2 at the injury site.  
After addition of the Gla residues, the propeptide is removed and 3 asparagine N-linked 
oligosaccharide chains are attached in the mature molecule, 2 in the first kringle 
domain and one in the B-domain. Thrombin’s zymogen, prothrombin (F2; 70 kDa), is 
then secreted into blood at a concentration of 1.2 μM. 
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Figure 5. Amino acid sequence of prepro-prothrombin. Prepro-prothrombin 
contains a signal peptide, propeptide, Gla domain, two Kringle domains, a light               
(A-chain) and heavy (B-chain) chain. The N-terminal sequence of prothrombin is 
indicated by an orange arrow. Gla residues are in the sequence as γ and the three ◊ 
indicate amide-linked carbohydrates at asparagines (N). F10a cleaves at red arrows and 
F2a at blue arrows. The serine protease catalytic center amino acids (His (H), Asp (D), 
and Ser (S)) are circled in red. F1.2 is the fragment between the orange arrow and the 
first (N-terminal) red arrow (modified figure according to Davie and Kulman). 
 
Prothrombin is converted to F2a by prothrombinase complex which consists of F10a, 
activated Factor 5 (F5a), and calcium ions complexed on the phospholipid surface of 
activated platelets (Figure 6). F10a activates prothrombin by cleaving Arg273-Thr274 
creating the intermediate prethrombin-2 consisting of combined A- and B-chains after 
releasing fragment 1.2 (Krishnaswamy, S., 1987). This intermediate is subsequently 
converted to F2a by F10a cleavage at Arg322-Ile323, separating the A- and B-chains 
that remain linked by a disulfide bridge (Bishop, P.D., 2006). The prothrombinase 
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complex with the coagulation accelerator F5a activates prothrombin to F2a much faster 
than F10a alone (Nesheim, M.E., 1979, Bishop, P.D., 2006, Nesheim, M.E, 1981).  
  
 
 
Figure 6. Activation of prothrombin. Prothrombin is activated by the prothrombinase 
complex to 42 KDa prethrombin-2a. Autocatalytic activation results in 40 KDa α-
thrombin splitting off the 13 amino acid N-terminal of the A-chain (modified figure 
according to Davie and Kulman).    
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The serine protease, F2a, consists of the 49 residue A-chain linked to the 259 residue B-
chain by a disulfide bridge (Figure 6). α-thrombin is formed when F2a is cleaved at 
Arg284 releasing a 13 residue peptide (Figure 7). Both F2a and α- thrombin (α-F2a) are 
active serine proteases (Davie, E.W, 2006). F2a is homologous to other serine 
proteases. The His∙∙∙Asp∙∙∙Ser catalytic center is in a cleft within the B-domain 
(Fehlhammer, H., 1977) and upon activation are brought into close proximity by salt 
bridges (Bode, W., 1992). The active site is surrounded by three surface loops (Bode, 
W., 1992; Di Cera, 1995; Dang, Q.D., 1997) and two charged surface areas (exosites) 
that create specificity for the respective substrates. F2a is removed quickly from the 
blood stream in vivo; however, in vitro, F2a can be degraded into less active products: 
β- and γ-thrombin (Figure 1.7). These degraded species result from proteolysis of the 
B-chain by plasmin, trypsin, (Boissel, J.P, 1984) F10a (Soslau, G., 2004) or F2a itself 
(Boissel, J.P., 1984). β-thrombin is formed when F2a cleaves the B-chain after Arg380 
and Arg391 (prothrombin numbering, Arg62 and Arg73 in F2a numbering) releasing a 
small 11 residue peptide important for recognizing fibrinogen thereby creating the B1 
and B2 fragments (Boissel, J.P, 1984). γ-thrombin is subsequently formed with the 
cleavage after Arg442 and Lys472 (prothrombin numbering, Arg123 and Arg154 in 
F2a numbering) resulting in the creation of the B3 and B4 fragments (Boissel, J.P. 
1984). The B-chain in β- and γ-thrombin are held together by noncovalent interactions 
and because they still contain the catalytic triad they retain some activity (Soslau, G., 
2004). 
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Figure 7. Autodegradation of thrombin. α-thrombin can be autolytically degraded to 
β- and γ-thrombin. This figure modifies the prothrombin schema by Davie and Kulman. 
 
 
Analytically, prothrombin is frequently activated to F2a by snake venom such as ecarin 
(Kornalik, F, 1975; Morita, T., 1976; Speijer, H., 1986).  
 
Thrombin as multifunctional molecule in hemostasis cleaves fibrinogen into fibrin, 
activates cofactors F5 and F8, activates protein C, activates factors F11 and F13, and 
activates thrombocytes. Thrombin is a promoter of angiogenesis by activating PAR1 
(protease-activated receptor-1) in platelet and endothelial cells.  PAR1 has been shown 
to mediate extensively thrombin-induced neurodegeneration and neuroprotection in the 
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brain. Therefore, thrombin and thrombin receptors represent novel therapeutic targets 
for treating neurodegenerative diseases (Weibo Luo, 2009). Thrombin and thrombin 
peptides are important in wound healing and tissue regeneration (Barbara Olszewska-
Pazdrak, 2009).  
Protein S is not a serine protease precursor but instead contains a thrombin-sensitive 
region (TSR) before the epidermal growth factor (EGF) domain and a sex hormone-
binding globulin (SHBG)-like domain in the COOH-terminus. (Joseph DR, Baker ME. 
1992). 
 
Vitamin K-dependent protein complexes are the essential components for establishing 
hemostatic balance. Each complex is composed of a serine protease enzyme [factor 7a, 
factor 9a, factor 10a, or thrombin (factor 2a)], a cofactor that functions as a surface 
receptor/enhancer for the enzyme [factor 8a (heavy- and light-chain), factor 5a (heavy- 
and light-chain), tissue factor (TF) or thrombomodulin (TM)], Ca2+, and a negatively 
charged membrane surface of cells (e.g., endothelial cells, monocytes, and platelets).  
There are 3 vitally important vitamin K-dependent complexes:  
extrinsic ten-ase (factor 7a-TF-PL-Ca2+),  
intrinsic ten-ase  (factor 9a-cofactor 8a-PL-Ca2+),  
prothrombinase (factor 10a-cofactor 5a-PL-Ca2+). 
 
Another vitamin K-dependent complex is the anticoagulant protein C-ase complex 
(thrombin-TM).  
 
When the serine protease enzyme is associated with its respective cofactor on an 
appropriate membrane surface with Ca2+, the specific reactions occur at an enhanced 
rate 104 to 109 -fold greater than the enzyme-substrate combination alone (Mann KG, 
1990).  
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1.1.4. Cofactor Proteins 
Two categories of procoagulant cofactor proteins are recognized: the soluble plasma 
derived procoagulant procofactors (cofactor 5 and cofactor 8) and the cell-bound 
cofactors (TF and TM). 
Factor 5 (F5) is a large single-chain glycoprotein that circulates in human plasma and 
20% of the total factor F5 is also in the alpha granules of human platelets (Tracy PB, 
1982). Factor 5a functions as both a factor 10a receptor and a positive modulator of 
factor 10a catalytic proteolytic potential in the prothrombinase complex (Mann KG, 
Kalafatis M. 2003). 
Factor 5a is proteolytically inactivated by activated protein C (PCa) (Mann KG et al. 
1997; Nicolaes GA, Dahlback B. 2002). A common genetic mutation (R506Q)  that 
introduces a glutamine (Gln) for an Arginin (R) at PCa-cleavage position 506 has been 
termed F5LEIDEN (PCa resistance syndrome) (Dahlback B, 1993; Bertina RM, 1994). 
Individuals with homozygous carriers F5LEIDEN defect have an 80-fold increase in risk 
of hypercoagulability with venous thrombosis compared to similar individuals with 
normal F5 (Kalafatis M, 1995).  
The mature antihemophilic factor (F8) is synthesized in hepatocytes and in the 
hepatic sinusoidal endothelial or Kupffer cells as a single-chain polypeptide. 
Insufficient expression of F8 or expression of nonfunctional F8 results in hemophilia A, 
one of the most common severe sex-linked hereditary bleeding disorders.  F8 circulates 
in plasma as noncovalent complex with the higher molecular weight (HMW) 
multimeric protein von Willebrand factor (vWF) (Leyte A, 1989). vWF regulates the 
synthesis and cofactor activity of F8 (Weiss HJ, 1977) and concentrates the F8 at the 
site of vascular injury (Sakariassen KS, 1979). vWF prevents premature interaction of 
F8 with phospholipid (PL) prior to F8 activation (Andersson LO, 1981) and protects F8 
from various PL dependent proteases, such as factor F9a, F10a, and PCa (O’Brien DP, 
1992; Nogami K, 1999; Fay PJ, 1991).  
The quantitative deficiency (Type 1) and complete deficiency (Type 3) of vWF or the 
qualitative deficiency (Type 2) of vWF results in a secondary decrease of F8 activity 
and a bleeding tendency known as von Willebrand disease (Hoyer LW. 1981). 
α-thrombin and activated serine protease factor 10 (F10a) cleave  Factor 8 to generate 
the heterotrimeric activated cofactor 8. Activated protein C (PCa) inactivates activated 
F8 by proteolytic cleavage in the presence of negatively charged PL (Eaton D et al. 
1986).  
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Tissue Factor (TF) (thromboplastin, CD142, coagulation factor III) is a glycosylated 
membrane single polypeptide chain protein consisting of extracellular protein 
composed of two fibronectin type III domains, hydrophobic membrane-spanning 
domain and short cytoplasmic domain (Morrissey JH et al. 1987; Paborsky LR, Harris 
RJ. 1990). TF is a type I integral membrane protein, which means that the amino-
terminus of the protein is located outside the cell, whereas the carboxy terminus is 
located inside the cell. The majority of the TF is in functionally inactive (encrypted) 
state. Upon cell lysis or stimulation, TF is activated (de-encrypted) and supports F7a 
binding and activation of F10 (Chen VM, 2006). Protein disulfide isomerase (PDI), 
glutathione and nitric oxide have all been implicated in mediating of de-encryption 
process. TF is abundant on the surface of cell including adventitial cells surrounding all 
blood vessels larger than capillaries, differentiating keratinocytes in the skin, and a 
number of epithelial-mesenchymal cell types, including those present in mucous 
membranes and many organs (brain, placenta, lung and prostate). TF antigen is present 
in the acellular core of atheromas, most likely derived from cells that have undergone 
necrosis (Marmur JD, 1996). TF is not normally expressed on vascular endothelial cells 
or monocytes. TF expression occurs during activation of monocytes/macrophages and 
endothelium, e.g. by tumor necrosis factor (TNFα), interleukin-1β (IL1β), or endotoxin 
(Geczy CL. 1994; Camerer E, 1996). TF is expressed during severe sepsis by 
endothelial cells in only a few, highly restricted areas, such as in the splenic 
microvasculature (Drake TA, 1993). Endothelial expression of TF has been observed in 
vivo in other conditions, including placental villitis (Faulk WP, 1990) and graft 
rejection (Blakely ML, 1994; Salom RN, 1998). TF may also circulate in the blood, 
associated with cell-derived membrane microvesicles as well as in a soluble, 
alternatively-spliced form (Giesen PL, 1999; Bogdanov VY, 2003). These 
microvesicles derive from lipid rafts on the surface of stimulated 
monocytes/macrophages, and might be capable of fusing with platelets, initiating 
coagulation (Del Conde, 2005). TF binds factor 7 or 7a with high affinity, resulting in a 
1:1 complex of the two proteins on the cell surface. Once bound to TF, factor F7 is 
rapidly converted to factor F7a by limited proteolysis (Nemerson Y, 1985). The TF:F7a 
complex is formed through direct capture of circulating factor 7a by TF or through 
capture of factor 7 by TF followed by conversion of the bound factor 7 to 7a. Once 
formed, the TF:F7a complex directly activates factor F10. 
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1.1.5. Intrinsic Pathway and contact system proteins 
The 3 proteins Factor 12 (F12; Hageman factor), prekallikrein (PK; Fletcher factor), 
high-molecular-weight kininogen (HMWK; Williams-Fitzgerald-Flaujeac factor), are 
the initial phase of the contact system (intrinsic hemostasis); the serpin C1 esterase 
inactivator (C1-ina) controls the proteolytic activity of F12a and kallikrein (K) (Figure 
8).  
The intrinsic pathway of coagulation is initiated by factor F12a, often in a reaction 
involving high molecular weight kininogen and plasma kallikrein. Contact with 
negatively charged surfaces induces a conformational change in zymogen F12 resulting 
in a small amount of activated F12 (F12a). F12a cleaves PK into active kallikrein, 
which in turn reciprocally activates the F12 zymogen (Figure 8). F12a or K initiate 
fibrin formation through F11 activation, K releases the inflammatory mediator 
bradykinin (BK). Binding of BK to the kinin B2 receptor (B2R) activates various 
proinflammatory signalling pathways that dilate vessels, induce chemotaxis of 
neutrophils, and increase vascular permeability and fluid efflux (”leakiness”).  
Individuals with factor F11 deficiency (hemophilia C) express variable bleeding 
disorders with surgical challenge, (Sidi A, 1978) thus are establishing an essential role 
for factor F11 in hemostasis. Formation of factor 11a appears to be catalyzed also by α-
thrombin as part of a positive feedback loop (Lawson JH, 1994).  
Factor F12 and prekallikrein are zymogens that are activated to generate serine 
proteases, and HMWK is a nonenzymatic procofactor. Activation of this pathway in 
vitro is accomplished when factor F12 autoactivates to factor 12a with exposure to 
foreign surfaces, including kaolin, dextran sulfate, and sulfatides (Schmaier AH, 2008; 
Wiggins RC, 1979; Silverberg M, 1980). Two main trigger types activate the intrinsic 
enzyme system: (delta)-negatively charged molecules and lipophilic molecules. The 
stimulation of thrombin generation by (delta)-negatively charged molecules depends on 
their maximal plasma concentration prior to plasma dilution (Stief TW, 2012a), and 
contact activation of coagulation depends on the maximal lipophilic trigger 
concentration in plasma prior to dilution (Stief TW, 2012b). The substrates for factor 
F12a, prekallikrein and factor F11, exist in a noncovalent complex with HMWK and 
become activated to kallikrein and factor F11a, respectively (Mandle RJ, 1976). The 
intrinsic pathway is positively or negatively regulated via cleavage of HMWK e.g. by 
factor 11a (Scott CF, 1984; Scott CF, 1985). These proteins are associated with the 
systemic inflammatory response syndrome, (Bone R: 1992; Schousboe I: 2008). 
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Biologic activation of the contact pathway system may be accomplished through 
assembly of these proteins on endothelial cell membranes; also prekallikrein is 
activated by an endothelial cell membrane cysteine protease (Schmaier AH, 1998; 
Rojkjaer R, 1998).  The accessory pathway is especially important in cardiopulmonary 
bypass because of contact between blood components and synthetic surfaces. 
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Figure 8.  Coagulation System. 
PL: phospholipids; TF: tissue factor; a: activated coagulation factors. 
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Hageman-Factor, F12, synthesized in the hepatocytes as single polypeptide chain, is 
the serine protease precursor of a β-globulin fraction of plasma (Griffin JH 1976).  Six 
distinct domains can be identified in a putative signal peptide sequence of Hageman 
factor: a type II region homologue to collagen-binding site in fibronectin, epidermal 
growth factor (EGF)-like domain, a type I homology or the fibrin finger in fibronectin, 
second EGF-like domain, a kringle (k) structure and a proline-rich region, and the large 
catalytic domain (Cool DE, 1987). F12a activates PK and F11 of coagulation (Kurachi 
K, 1980), and C1 of complement (Ghebrehiwet B, 1983). F12a downregulates the Fc 
receptor on monocytes (Chien P, 1988), releases interleukin 1 (IL-1) and IL-6 from 
monocytes and macrophages (Toossi Z, et al. 1992), and stimulates neutrophils 
(Wachtfogel YT, 1986). Two pathways for activation of factor 12 can be identified: 
Plasma proteinases-dependent activation and surface/contact-dependent activation. 
Plasma proteinases, including plasma kallikrein, trypsin or plasmin activate F12 to 
F12a, cleaving at Arg353-Val354 and generating a two-chain molecule composed of a 
heavy chain and a light chain, held together by a single disulfide bridge (Cool DE, 
1985). Trypsin, plasmin, and kallikrein can proteolytically activate the zymogen F12 to 
F12a or to β-F12a (Revak SD, 1977; Cochrane CG, 1973). The 80kDa form of 
activated F12 has the ability to bind to negatively charged surfaces and activate F11. 
Because the 28-30kDa enzymatic form of F12 (β-F12a) has no heavy chain, it has no 
surface-binding properties or ability to activate F11 but retains its ability to activate PK 
and C1 (Revak SD, Cochrane CG, et al. 1978; Revak SD, et al. 1976). Components, 
which include fatty acids, high concentrations of dextran sulfate or phosphatidyl 
inositol phosphate, cerebroside sulfates (Tans G, 1983), glycosaminoglycans (Hojima 
Y, 1984), are very potent activators of F12 via surface-dependent activation pathway. 
The major plasma protease inhibitor of F12a and K is C1-ina, which binds both proteins 
in 1:1 stoichiometry with concomitant loss of activity of both, protease and inactivator. 
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Prekallikrein (PK; Fletcher factor) and High-molecular-weight kininogen (HK; 
Williams-Fitzgerald-Flaujeac factor) 
PK, synthesized at high levels in pancreas, kidney, testis, spleen, and prostate, but at 
highest levels in the liver (Neth P, 2001), is a fast γ-globulin with an isoelectric point of 
8.7 (McConnell DJ, 1970) and with a plasma concentration of about 42 µg per ml (0.49 
µM) (Fisher CA, 1982). Approximately 75% of plasma PK circulates bound to HK 
(Mandle R Jr, 1976; Scott CF, 1980), and only 25% circulates as free PK. HK is a 120 
kDa, β-globulin glycoprotein that circulates in plasma at a concentration of 670 nM (80 
µg/ml) and is a member of the cystatin family of cysteine protease inhibitors. The two 
plasma kininogens, HK and low-molecular-weight kininogen (LK) are known. In 
humans and rodents, HK and LK are predominantly expressed in the liver but can also 
be found in endothelial cells, granulocytes, renal tubular cells, and α-granules of 
platelets. The conversion of PK to kallikrein, its active form, is catalyzed by F12a on a 
surface to which HK is bound or by F12 fragment in the fluid phase (Wuepper KD, 
1972). Kallikrein catalyzes an autolytic cleavage at Lys140-Ala141, resulting in β-
kallikrein (Colman RW, 1985). This enzyme exhibits decreased coagulation activity, a 
diminished rate of cleavage of HK, and decreased ability to stimulate neutrophils. 
Plasma kallikrein activates pro-urokinase (Ichinose A, 1986), pro-renin (Sealey JE, 
1978), and F12 (Fujikawa K, 1980), and cleaves HK, thereby releasing bradykinin 
(BK) (Jacobsen S, 1967). HK inhibits adhesion of neutrophils to blood-compatible 
surfaces under flow conditions (Yung LL, 1996), enhances cellular fibrinolysis (Lin Y, 
1997), and inhibits thrombin-induced platelet activation. In plasma, kallikrein is 
inactivated by the serpin C1-ina, forming a 1:1 stoichiometric complex with kallikrein 
(Gigli I, 1970), resulting in loss of both, the proteolytic activity of the enzyme and the 
inhibitory function of C1-ina (Schapira M, 1981). Kallikrein bound in α2-
macroglobulin inhibits the release of BK from kininogens, but it does not inhibit its 
amidolytic activity. Antithrombin 3 (AT-3), in the presence or absence of heparin, is an 
inefficient inhibitor of kallikrein. 
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1.2. Hemostasis Screening Assays: Use and Interpretation 
 
Routine assays of usual coagulation testing are the prothrombin time (PT), partial 
thromboplastin time (APTT) and Thrombin Time (TT) (Figure 9). 
 
 
 
 
 
Figure 9. The coagulation cascade. Blood coagulation with separate intrinsic (red) 
and extrinsic (blue) pathways converging on the common pathway (green) with the 
generation of F10a. 
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1.2.1. PT (prothrombin time, Thromboplastin time, Quick-Test) 
The prothrombin time (PT) test is used mainly to control oral anticoagulant therapy 
(OAT). PT is the most widely used coagulation test in clinical laboratories. The number 
of tests is increasing about 10 % a year. OAT is based on the ability of Phenprocoumon 
(Marcumar), Coumadin (Warfarin) and Acenocoumarol (Sintrom) as a vitamin K 
antagonists, to slow down the synthesis of active coagulation factors in the liver (F2, 
F7, F9, and F10). Marcumar, Warfarin and Sintrom medications require continuous 
monitoring to prevent the serious consequences of thrombosis or bleeding (Odén A, 
2002). Mortality has been seen to be strongly related to the level of the international 
normalized ratio (INR), and accuracy in patient care is very important. 
The prothrombin time is commonly measured by either the "Quick PT", which is based 
on the technique described by Quick and co-workers in 1935 (Quick AJ, Stanley-
Brown M, Bancroft FW. 1935; Quick AJ. 1935) or by the "Owren PT" (Owren PA. 
1959) (combined thromboplastin reagent). 
The PT measures the time required for the following reaction: 
Plasma+Thromboplastin+Ca2+→Fibrin Clot 
Thromboplastins are reagent preparations rich in tissue factor and phospholipids.   The 
prothrombin time (PT) is used to assess the extrinsic pathway of clotting, which 
consists of tissue factor and factor F7, and coagulation factors in the common pathway 
(factors F2 [prothrombin], F5, F10, and fibrinogen). In this test, clotting is initiated by 
recalcifying citrated patient plasma in the presence of thromboplastin (tissue factor). 
The endpoint for the PT (and also for the partial thromboplastin and thrombin times) is 
the time (in seconds) for the formation of a fibrin clot, which is detected by visual, 
optical, or electromechanical means. The sensitivity of the PT to reduced activity of the 
vitamin K-dependent factors within this pathway (ie, factors F7, F10, and F2; especially 
factor F7) comprises the rationale for the use of the PT to monitor Marcumar, Warfarin 
and Sintrom medications therapy. 
Results of the prothrombin time can be expressed in one of four different ways: 
 PT with control value: The patient’s PT (in seconds) is reported along with the 
PT obtained from control (normal) plasma. The control value is needed since 
there can be significant inter-laboratory variability in the PT with different 
reagent/instrument combinations. 
 PT expressed as INR: In order to promote standardization of the PT for 
monitoring oral anticoagulant therapy, the World Health Organization (WHO) 
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developed an international reference thromboplastin, currently recombinant 
tissue factor, and recommended that the PT ratio be expressed as the INR (Hirsh 
J, Poller L. 1994). This allows values of the PT from various locations to be 
directly compared, as may happen when a patient taking Marcumar, Warfarin 
and Sintrom has blood sampled at different laboratories.  
Measurement of INR: The INR, which compensates for differences in 
sensitivity of various PT reagents to the effects of warfarin, is used to monitor 
warfarin therapy (Hirsh J, Poller L. 1994).  The INR is calculated from the 
following formula:  INR = [Patient PT / Normal PT]ISI 
The ISI (international sensitivity index) should be determined for each PT 
reagent and instrument combination. Although the ISI is traceable to an 
international reference thromboplastin reagent, it is useful to have the ISI value 
confirmed within each laboratory, since this may be affected by differences in 
handling of the reagents and the type of equipment used (Becker DM, 1993; van 
den Besselaar AM, 1999). The control value for the PT is the mean normal 
prothrombin time for the laboratory, and should be determined from ≥20 fresh 
normal plasmas handled identically to patient material. An apparatus that allows 
the patient to monitor warfarin therapy at home is now available. 
 Prothrombin time ratio (PTr): The patient’s PT is expressed as a ratio, where 
PTr = (patient PT ÷ control PT). As an example, a PTr >1.2 was associated with 
a significantly increased risk of acute traumatic coagulopathy in a large 
multicenter retrospective study (Frith D, 2010). In this study, reagents used had 
similar sensitivities (ISI range 1.03-1.09). A limitation of this method is that 
reagent/instrument variability may affect the results. 
 
The PT has several disadvantages (Stief TW, 2008a). First, anticoagulants not always 
induce the respective test inhibition. Second, the normal range of extrinsic haemostasis 
is too blunted and not truly represented. Third, patients prone to hyper-activated 
extrinsic pathway are not detected. Fourth, fibrinogen/fibrin concentration influences 
the test result. Fifth, plasma matrix is changed significantly in the assay, and sixth, 
assay results are not IU/ml thrombin but coagulation seconds, which requires special 
hemostasis machines. 
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1.2.2. Activated partial thromboplastin time (APTT) 
The APTT was first described in 1953 by Langdell et al. Kaolin cephalin clotting time is 
a historic name for the activated partial thromboplastin time.  
The activated partial thromboplastin time (APTT or PTT) is used to test the intrinsic 
coagulation pathway (prekallikrein, high molecular weight kininogen, factors F12, F11, 
F9, and F8) and final common pathway (factors F2, F5, F10, and fibrinogen), and to 
monitor heparin therapy.  
The test is performed by recalcifying citrated plasma in the presence of a 
thromboplastic material that does not have tissue factor activity (therefore: partial 
thromboplastin) and a negatively charged substance (eg, ellagic acid, celite, kaolin, 
silica), which results in contact factor activation, thereby initiating coagulation via the 
intrinsic clotting pathway (Schmaier AH. 1997).  
The APTT measures the time required for the following reaction:  
Plasma+Phospholipid+Activator+Ca2+→Fibrin Clot 
Clot formation occurs via the intrinsic and common pathway, involving high molecular 
weight kininogen, prekallikrein, factors F12, F11, F10, F9, F8, F5, and F2, and 
fibrinogen (Van Cott EM, 2001). There are four etiologies to consider when the APTT 
is elevated: First, factor deficiency. Second, lupus inhibitors. Third, factor inhibitors, 
and Fourth, heparin. 
The importance of the APTT for monitoring UFH therapy is based on:  
1. Tests should measure the physiologic anticoagulant effect rather than simply 
providing a heparin concentration.  
2. The APTT is widely available with relatively short turnaround time, has good 
reproducibility, and is inexpensive.  
3. Clinicians have decades of experience with the APTT and have achieved a comfort 
level with its use for UFH monitoring.  
4. Until recently there have not been good alternatives.  
The APTT also possesses severe limitations (Hirsh J, 2004; Olson JD, 1998):  
1. The APTT does not measure the clinically most important heparin type that is low-
molecular weight heparin. 
2. The APTT is a non-standard assay so therapeutic ranges must be established in each 
laboratory. Different types of heparin may produce different PTT response curves.  
3. The APTT is useful only for monitoring therapeutic intravenous doses or high-dose 
subcutaneous UFH therapy. The APTT is not useful for standard-dose subcutaneous 
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therapy, due to limited APTT response, or for the high-dose iv UFH required for 
cardiac catheterization or other procedures, due to an excessive APTT response.  
4. The APTT is affected by variables other than UFH, including increased 
concentrations of factor F8 and fibrinogen, decreased concentrations of AT or intrinsic 
and common pathway proteins, lupus anticoagulant, and thrombolytic agents. When 
lupus anticoagulants are present, the APTT becomes unpredictable to test the response 
to UFH and should not be used.  
5. The routine APTT only detects 30% of patients with APLA and are inadequate as a 
single test for APLA (Antiphospholipid antibodies) screening. One can increase 
sensitivity by using different APTT reagents. 
6. The APTT does not adequately respond to the new oral anticoagulants rivaroxaban 
or dabigatran, neither to hirudin. 
 
1.2.3. Thrombin Time (TT): The TT measures the time required for the following 
reaction:   
Plasma+Thrombin→Fibrin Clot 
The Thrombin time test is performed by adding thrombin to plasma. The added 
thrombin directly clots fibrinogen. The TT is only affected that interfere with thrombin 
or fibrinogen. The TT is elevated in DIC (FSPs interfere with polymerization), low 
fibrinogen levels, dysfibrinogenemia, uremia and in the presence of Heparin (very 
sensitive). 
 
 
1.2.4. Activated clotting time (ACT) 
The activated clotting time (ACT) is a whole-blood clotting test commonly used to 
monitor high-dose UFH therapy, particularly cardiac catheterization and 
cardiopulmonary bypass procedures. (Olson JD, Arkin CF, et al. 1998)  
The ACT consists of the following reaction: 
Whole Blood+Particulate Activator→Fibrin Clot 
Celite and kaolin are commonly used as activators. Typically, the ACT is a point-of 
care test because non-anticoagulated blood specimens cannot be transported to a central 
laboratory quickly enough to avoid pre-test activation of clotting.  
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The ACT offers several advantages for UFH monitoring:  
1. The ACT has a wide dose-response range so it can be used for assessing high-dose 
UFH therapy.  
2. The ACT is simple to perform and results are available with rapid turnaround time. 
The rapid turnaround facilitates its use in assessing both induction and reversal of UFH 
anticoagulation in near-real-time during procedures.  
3. Extensive clinical experience over several decades provides a high level of 
familiarity and comfort with its use.  
4. Suitable alternatives are not readily available. Consequently, the ACT is widely used 
for high-dose UFH management. 
The ACT also has several important limitations and drawbacks.  
1. The ACT is non-standard and imprecise. (Bosch YP, 2006) 
2. Since non-anticoagulated blood is used, results are affected by deficiencies in 
specimen collection and application technique, including delayed application of 
specimens.  
3. The ACT reaction follows the same pathways as the PTT reaction, so the ACT is 
affected by the same biological variables. In addition, because whole blood is used, the 
ACT is also affected by variations in platelet count inasmuch as platelets provide 
phospholipid surfaces for reactions of the intrinsic and common pathways. 
By contrast, in the PTT assay phospholipid is provided as a reagent in a controlled 
amount.  
4. Although the dose-response of the ACT extends into the standard-dose UFH range, it 
is less precise and offers no advantages over the PTT for this use.  
5. Many ACT analyzers have only basic functionality and cannot be interfaced with 
information systems for data management. 
 
1.2.5. Anti-F10a Assay 
 
The heparin anti-F10a assay, or factor F10a inhibition test, is increasingly used to 
supplement or replace the PTT for monitoring heparin therapy (Olson JD, 1998). The 
principle of the anti-F10a assay is the inhibition of factor F10a by AT-3-heparin 
complexes, as illustrated in the following reactions: 
AT−Heparin+F10a→AT−Heparin−F10a+Residual F10a 
Residual F10a+Substrate→Signal 
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The anti-F10a assay has several favourable characteristics:  
1. The anti-F10a assay is simple to perform and automatable on many coagulation 
analyzers.  
2. Citrated specimens used for other coagulation tests may be used without additional 
special handling.  
3. The test is not affected by coagulation factor concentrations, lupus anticoagulants, or 
other biological variables.  
4. The anti-F10a assay is sensitive to the anticoagulant effect of LMWH and 
fondaparinux. 
5. The anti-F10a assay can theoretically be standardized to provide consistency 
between laboratories and facilitate the adoption of common therapeutic ranges. 
 
Anti-F10a assays have limitations:  
1. The anti-F10a assay is not an F10a generation assay (see APTT), it just measures the 
antigenic concentration of an anticoagulant. 
2. The anti-F10a assay is much more expensive than the APTT.  
3. It may not be financially or technically feasible to offer the anti-F10a assay in small 
laboratories, depending on test volume and instrumentation.  
4. Different UFH preparations may yield different standard curves. It is generally not 
feasible to establish a unique standard curve for every UFH preparation, so the potential 
exists for the standard curve of an anti-F10a assay to not be representative of the 
anticoagulant response for some UFH preparations. The same limitation applies to 
LWMH preparations. 
 
 
1.2.6. Phospholipid-dependent coagulation assays (PdCAs): 
PdCAs are used to optimize identification of the LA (lupus anticoagulant). Test options 
include the PTT, dilute PT, dilute Russell’s viper venom time (dRVVT), kaolin clotting 
time (KCT), Taipan venom test (TVT) and Textarin time (Triplett DA, 2002 ; Wisloff 
F, 2003).  
 Dilute Russel viper venom time (dRVVT): This test is very sensitive to any 
interference with phospholipids and is very sensitive to Russel Viper venom 
which directly activates factor F10 and is very sensitive to phospholipids. 
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 Kaolin cloting time (KCT): This test uses no added phospholipids and is a 
sensitive test to detect APLA. However, it is technically demanding to do 
properly. 
 Platelet neutralization test: This test takes a coagulation reaction that is 
prolonged by plasma and does not correct with a 50:50 mix. Extracts of platelet 
phospholipids are added to the plasma and an APTT is performed. The platetet 
phopholipid is very avid for APLA and ``soaks up`` the antiphospholipid 
antibody and corrects the APTT. If the APTT corrects with addition of platelets 
this is diagnostic for APLA. 
 Hexagonal phospholipids neutralization: This test is based on the same 
principle as the platelet neutralization test but it uses hexagonal phospholipids 
which is more specific for APLA. Current test kits use hexagonal PL also have 
added plasma and inhibitors of heparin. The additional reagents allow this assay 
for lupus inhibitors to be performed on anticoagulated patients. 
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1.3. Anticoagulants: classification, pharmacology 
Antithrombotic drugs are used for prevention and treatment of thrombosis. Targeting 
the components of thrombi, these agents include  
1. Antiplatelet drugs  
2. Anticoagulants  
3. Fibrinolytic agents 
Anticoagulants had been divided into parenteral and oral anticoagulants. Currently 
available parenteral anticoagulants include  
1. Unfractionated Heparin (UFH) 
2. Low-molecular-weight Heparins (LMWHs) 
3. Fondaparinux, a synthetic pentasaccharide. 
4. Heparin-related sulphated glycosaminoglycans (SGAG; heparinoids) include heparin 
derivatives such as danaparoid, dermatan sulfate, pentosan polysulfate, apolate, 
suleparoid, and sulodexide. 
 
The usual oral anticoagulants have been the vitamin K antagonists (Phenprocoumon 
(Marcumar), Coumadin (Warfarin) and Acenocoumarol (Sintrom) derivatives). 
Dabigatran etexilate, an oral thrombin inhibitor, and rivaroxaban, an oral Factor F10a 
inhibitor, are now licensed in the US and in Europe. (Haines ST, 1995; Nutescu EA, 
2005; 2006) (Table 1). 
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Drug Method of 
Preparation 
Mean 
Molecular 
Weight 
(Daltons) 
Plasma 
Half-Life 
Anti-F10a:Anti-F2a 
Activity 
Bioavailability 
Unfractionated 
heparin (UFH) 
Extracted from 
porcine gut mucosa 
or beef lung 
≈15,000 30–90 min 
(dose 
dependent) 
1:1 SC: 30–70% 
(dose 
dependent) 
Low molecular weight heparins (LMWHs) 
Ardeparin  Peroxidative 
depolymerization 
≈6,000 200 min 1.9:1 SC: 90% 
Dalteparin  Nitrous acid 
depolymerization 
≈6,000 119–139 
min 
2.7:1 SC: 87% 
Enoxaparin  Benzoylation and 
alkaline 
depolymerization 
≈4,200 129–180 
min 
3.8:1 SC: 92% 
Nadroparin  Nitrous acid 
depolymerization 
≈4,500 132–162 
min 
3.6:1 SC: 99% 
Tinzaparin  Heparinase 
digestion 
≈4,500 111–234 
min 
2.8:1 SC: 90% 
Heparinoid 
Danaparoid  Extracted from 
porcine gut mucosa 
≈6,500 22–24 h 20:1 SC: 95% 
Anti–factor F10a inhibitors 
Fondaparinux  Synthetic 1,728 15–18 h 100% anti-F10a SC: 100% 
Idraparinux  Synthetic ≈1,700 ≈80 h 100% anti-F10a SC: 100% 
Direct thrombin F2a inhibitors 
Argatroban Synthetic 509 30–50 min 100% anti-F2a  
Bivalirudin Semisynthetic 2,180 25 min 100% anti-F2a  
Desirudin  Recombinant DNA 
technology 
6,964 120 min 100% anti-F2a SC: >90% 
Lepirudin  Recombinant DNA 
technology 
6,980 80 min 100% anti-F2a SC: 70% 
Dabigatran Synthetic 471 14 h 100% anti-F2a Oral: 7% 
Vitamin K antagonists 
Warfarin Synthetic 330 40 h   1:1 Oral: 90–100% 
 
 
Table 1. anticoagulants: systematic classification and pharmacology 
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1.3.1. Unfractionated Heparin 
 
1.3.1.1. History of Heparin discovery and biochemical structure 
The heparin story (Bigelow, 1990) began in 1916 at Johns Hopkins University in 
Baltimore. Jay McLean isolated an extract of dog liver, which inhibited blood 
coagulation (Bick RL. 2002). Howell determined that heparin was not phosphorylated 
and was a carbohydrate. The student Sune Bergstrom identified glucosamine (GlcN) as 
a sugar component in heparin while working with Eric Jorpes in Sweden. Jorpes 
established that heparin contained a high proportion of sulfo groups and determined 
that the GlcN residue in heparin was primarily N-sulfonated. By the 1920s, several 
groups were manufacturing heparin.  
In the 1930s, Gordon Murry in Toronto and Clarence Crafoord in Stockholm 
successfully began using heparin in surgery patients. Since the 1930s, clinicians have 
used unfractionated heparin (UFH) for the prevention and treatment of thrombosis 
(Hirsh J, 2004). Like all other natural polysaccharides, heparin is a polydisperse 
mixture containing a large number of chains having different molecular weights (Ahsan 
A, 1995; Mulloy B, 1997). The polydispersity (the ratio of overnormal weight in 
relation to averaged molecular weight) of pharmaceutical heparin is 1.1–1.6 (Ahsan A, 
1995). The chains making up polydisperse pharmaceutical grade heparin range from 
5,000 to over 40,000 Da (Linhardt RJ, 1997) and contain a significant level of sequence 
heterogeneity.  Heparin is composed of a major (75–95%) trisulfated disaccharide 
repeating unit (Figure 10, A), a 2-O-sulfo-α-L-iduronic acid  1 → 4 linked to 6-O-sulfo-
N-sulfo-α-D-glucosamine IdoA2S(1 → 4)GlcNS6S, as well as a number of additional 
minor disaccharides structures corresponding to its variable sequences (Figure 10, B) 
(Linhardt RJ, 1988; Loganathan D, 1990; Pervin A, 1995). There are some fully 
sulfated heparin chains that are simply composed of uniform repeating sequences of 
trisulfated disaccharide. Most heparin chains, however, have an intermediate level of 
sulfation (2.5 sulfo groups/disaccharide) and are composed of long segments of fully 
sulfated sequences with intervening undersulfated domains. Some chains, primarily 
composed undersulfated sequences, are classified as heparan sulfate, a closely related 
sulphated glycosaminoglycan (SGAG).  
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Figure 10. The structures of the major (A) and minor (B) repeating disaccharides 
comprising heparin: X =SO3- or H, and Y =SO3- or COCH3. 
 
 
A unique saccharide combination comprises the antithrombin-3 (AT-3) pentasaccharide 
binding site, GlcNAc/NS6S → GlcA → GlcNS3S,6S → IdoA2S → GlcNS6S, 
important for heparin’s anticoagulant activity (Figure 11) (Lindahl U, 1980; Atha DH, 
1985). 
 
Figure 11. Heparin’s antithrombin-3 binding site and its structural variants. 
GlcA = β-D-glucuronic acid; IdoA = α-L-iduronic acid; IdoA (2S) = 2-O-sulfo-α-L-iduronic 
acid GlcNAc = 2-deoxy-2-acetamido-α-D-glucopyranosyl; GlcNS = 2-deoxy-2-sulfamido-α-D-
glucopyranosyl; GlcNS(6S) = 2-deoxy-2-sulfamido-α-D-glucopyranosyl-6-O-sulfate 
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AT-3 binds to a specific AT-3 pentasaccharide sequence in heparin (Lindahl U, 1980; 
Atha DH, 1985). When heparin binds to the serine protease inhibitor AT-3, AT-3 
undergoes a conformational change resulting in the inhibition of thrombin and other 
coagulation cascade proteases (Munoz EM, 2004; Linhardt RJ, 2003). Only a third of 
the chains comprising pharmaceutical-grade heparin contain an AT-3 binding site, and 
these are called “high affinity heparin” (Edens RE, 1995). In contrast, heparin interacts 
with low specificity to thrombin based on its high negative charge density. Thus, if a 
heparin chain containing an AT-3 binding site is sufficiently long to accommodate 
thrombin, it can form a tertiary complex, inhibiting thrombin’s conversion of soluble 
fibrinogen to an insoluble fibrin clot. Low molecular weight heparins (LMWHs) are 
prepared through the controlled chemical and enzymatic depolymerization of heparin 
(Barrowcliffe TW, 1995). LMWH chains are often too small to accommodate thrombin 
in a ternary complex, and thus inhibit the coagulation cascade primarily through 
coagulation factor 10a.  The clinical value of LMWHs comes primarily from their 
enhanced subcutaneous bioavailability (Linhardt RJ, 2003).  
Heparin and other glycosaminoglycans are generally isolated by extraction from animal 
tissues, but some simple unsulfated glycosaminoglycans can be obtained from the 
capsules of bacteria (Casu B, 1989; Hook M, 1984; Chakrabarti B, 1980; Casu B. 
1979). Heparins from tissues of various species also differ in structure and activity 
(Table 2) (Loganathan D, 1990).  
 
Tissue N-Acetyl AT-3 
binding sites 
N-Sulfo AT-3 
binding sites 
Trisulfated 
disaccharides 
Disulfated 
disaccharides 
Porcine intestine 0.5 (0.3–0.7) 0.1   10 (10–15) 1.2 (1–2) 
Bovine lung 0.3 0.3 14 1.0 
Bovine intestine 0.3 0.3 10 1.7 
Ovine intestine 0.7 0.4 11 1.4 
 
Table 2. Structural variability of heparins between different tissues with different 
average number in a single heparin chain 
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For example, porcine intestinal heparin has an AT-3 binding site primarily containing 
an N-acetyl (NAc) group, ( Linhardt RJ, 1999) while bovine lung heparin primarily 
contains an N-sulfo (NS) group, resulting in slight differences in their affinities for AT-
3 (Linhardt RJ, 2003). Pharmaceutical heparins are most commonly isolated in tons 
quantities from porcine intestines (Coyne E, 1981). The disaccharide composition of 
individual porcine intestinal heparins can also differ (Table 2) (Linhardt RJ, 1988). 
Some porcine intestinal heparin is prepared from porcine intestinal mucosa, scraped 
from the intestine, while other preparations use the whole intestine (“hashed pork 
guts”). These two raw materials contain differing amounts of structurally related 
heparan sulfate that can carry over into the final pharmaceutical product.  
Today, heparin is often described in the literature as standard heparin or unfractionated 
heparin to distinguish it from low-molecular weight heparins. Unfractionated heparin is 
an intravenuosly or subcutaneously administered anticoagulant, widely used for the 
treatment and prevention of thromboembolic events, including deep venous thrombosis, 
pulmonary embolism, stroke, myocardial infarction, unstable angina, and some cases of 
disseminated intravascular coagulation (DIC), and for anticoagulation during 
cardiopulmonary bypass, percutaneous coronary intervention, and extracorporeal 
membrane oxygenation (ECMO) procedures (Hirsh J, Raschke R. 2004).  
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1.3.1.2. Mechanism of Action of Unfractionated Heparin 
 
UFH is a heterogeneous group of anionic mucopolysaccharides, called sulphated 
glycosaminoglycans (SGAGs), with anticoagulant properties. The molecular weight 
ranges from 3,000 to 30,000 daltons, averaging 15,000-18,000 daltons, around 45-50 
saccharides. It carries the name heparin because it was originally extracted from liver 
(Hirsh J, Raschke R. 2004). The term “heparin” generally refers to unfractionated 
heparin, so named because of its heterogeneity in size and function. Heparin exerts its 
anticoagulant effect via several mechanisms: 
1. Binding to AT-3 and catalyzing inactivation of factors F2a and F10a: major 
mechanism for anticoagulant effect, produced by only one third of heparin 
molecules (those containing the unique AT-3-binding pentasaccharide) (Lam 
LH, 1976; Andersson LO, 1976). 
2. Binding to heparin cofactor-2 (HC-2) and catalyzing inactivation of factor 
F2a: anticoagulant effect requires high concentrations of heparin and 
independent of the pentasaccharide (Tollefsen DM, 1982) 
3. Binding to factor F9a requires very high concentrations of heparin, and is 
independent of AT-3 or HC-2 (Weitz JI, 1999). 
4. Binding to platelets inhibits platelets function and contributes to the 
hemorrhagic effects of heparin: high-molecular-weight fractions have greater 
effect than low-molecular-weight fractions (Eika C, 1971; Kelton JG, 1980). 
5. Heparin displaces TFPI (tissue factor pathway inhibitor) bound to 
endogenous SGAGs on the surface of the endothelium (Arieru RA, 1994; Holst 
J, 1993). Repeated heparin administration releases TFPI without diminishing 
releasability with TFPI levels reaching 2- to 10-fold over baseline. LMWHs 
have a variable effect on TFPI release (Vogel GM, 1989). Neutralization of 
heparin by protamine sulfate results in a dramatic decrease in the plasma TFPI 
level (Harenberg J, 1993). 
But the most important by far is the potentiation of the serine protease inactivator 
antithrombin 3 (AT-3). By itself, AT-3 is a slow inhibitor of thrombin. Heparin binds to 
AT-3 through a specific pentasaccharide sequence, inducing a conformational change 
that increases the rate of binding to thrombin by 1000-fold (Figure 12). Heparin-AT-3 
also inhibits factor F10a, and to a much lesser degree factor F9a, factor F7a-tissue 
factor complex, factor F11a (factor F12a, kallikrein). It indirectly inhibits thrombin-
induced activation of platelets and factors F5 and F8. Thrombin is 10-fold more 
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sensitive to heparin-AT-3 inhibition than is factor 10a, and factor F10a is more 
sensitive than the other coagulation factors. AT-3 binds covalently to the active serine 
centers of coagulation factors, then heparin dissociates and can be reutilized. Inhibition 
of thrombin by heparin-AT-3 requires heparin molecules of 18 or more saccharides. 
Complexes with small heparin molecules inhibit factor F10a and other factors, but not 
thrombin.  
 
 
Figure 12. Pharmacologic activity of unfractionated heparin (UFH).  
 
At high concentrations, UFH molecules of 24 or more saccharides, with or without the 
high-affinity pentasaccharide, bind to heparin cofactor 2 and catalyze the inactivation 
of thrombin. Heparin is a 10000 to 20000 Dalton sized polynegative molecule that not 
only activates antithrombin-3 but also pre-kallikrein or F12; kallikrein or F12a initiate 
the intrinsic phase of hemostasis generating thrombin that activates F5 and F8, the two 
main accelerators of hemostasis. Small heparin derivatives of about 6000 Dalton, such 
as the low molecular weight heparin enoxaparin, still activate AT-3 but they do not 
seem to significantly trigger intrinsic hemostasis (Stief TW. 2007a). Heparin binds to 
von Willebrand factor (vWF), inhibiting platelet adhesion mediated by vWF (Hirsh J, 
Raschke R. 2004). Heparin inhibits the secretion of aldosterone and so may cause 
hyperkalaemia (Oster JR, 1995). Although all patients treated with heparin may 
develop reduced aldosterone concentrations, most are able to compensate through the 
reninangiotensin system.  Patients on prolonged heparin therapy or those unable to 
compensate, such as patients with diabetes mellitus or renal impairment or those also 
receiving potassium-sparing drugs such as ACE inhibitors, may present with K+ 
increase symptoms. Long term use of heparin for treatment and prophylaxis of 
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thromboembolism in pregnant women has been complicated with heparin-induced 
osteoporosis in pregnancy (Nelson-Piercy C.1998). Symptomatic osteoporosis in 
pregnants given heparin long term occurs in about 2% (Bates SM, 2008). Subclinical 
reduction in bone density occurs in up to one-third of patients, (Bates SM, 2008) but it 
is not possible to predict which of these patients will develop osteoporotic fractures. 
Use of low-molecular-weight heparins is associated with a lower risk of heparin-
induced osteoporosis (Bates SM, 2008). Using of heparin leads to the release of 
lipoprotein lipase into the plasma. Postprandial lipidaemia is reduced due to increased 
hydrolysis of triglycerides into free fatty acids and glycerol (Riemersma RA, 1981). 
With long-term use reserves of lipoprotein lipase may be depleted; severe 
hypertriglyceridaemia reported in a pregnant woman was attributed to long-term 
heparin prophylaxis that was thought to have resulted in lipoprotein lipase deficiency 
(Watts GF, 1991). Increaseing in liver transaminase in patients given heparin, usually 
reversible on discontinuing of heparin admenstration, have been reported with 
therapeutic (Sonnenblick M, 1975; Dukes GE, 1984) or prophylactic (Monreal M, 
1989) doses of heparin. Dermal necrosis is a rare dermatological complication of 
heparin use (Ulrick PJ, 1984; Fowlie J, 1990). It may be a localised reaction at the site 
of subcutaneous injection or possibly be related to heparin-induced thrombocytopenia. 
Eczematous plaque reactions have developed several days after starting subcutaneous 
heparin. An intravenous hypersensitivity reaction has been implicated (Bircher AJ, 
1990). Low-molecular-weight heparins may be an alternative but cross-reactivity can 
occur (O’Donnell BF, 1993). Heparin has been associated with the development of 
thrombocytopenia (HIT). Thrombocytopenia induced by heparin may be of two types. 
HIT-1 is an acute, but usually mild, fall in platelet count occurring within 1 to 4 days of 
starting therapy and which often resolves without stopping treatment. A direct effect of 
heparin on platelet aggregation appears to be responsible. HIT-2 has an immunological 
basis and is more serious. It usually occurs after 5 to 11 days although its onset may be 
more rapid in patients previously exposed to heparin; (Warkentin TE, 2001) it is often 
associated with thromboembolic complications due to platelet-rich thrombi (the ‘white 
clot syndrome’) or, more rarely, bleeding. This type of thrombocytopenia appears to 
occur more often with bovine heparin than with heparin from other species, (Bell WR, 
1980) and least frequently with lowmolecular-weight-heparins; (Warkentin T, 2008) 
the mechanism appears to be development of antibodies to a complex formed between 
heparin and platelet factor-4 (a cationic protein released from the α granules during 
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platelet activation, neutralizes heparin and prevents it from interacting with AT-3), 
which then cause platelet activation and thrombin generation (Menajovsky LB, 2005).  
 
Heparin has been postulated to have an antineoplastic effect due to a decrease in 
neoangiogenesis, possibly mediated by binding to vascular endothelial growth factors, 
cytokines, and adhesion molecules. Heparin inhibits the release of P-selectin from 
platelets and endothelial cells and also binds to P-selectin and L-selectin and 
CD11b/CD18 expressed on leukocytes (anti-inflammatory effect). 
Heparin (sodium or calcium salt) is administered either by intravenous bolus ingection 
followed by continuous infusion or subcutaneous injection. Upon entering the blood 
stream, heparin binds to a variety of plasma proteins, thereby lowering its 
bioavailability and producing a variable anticoagulant response. Major binding proteins 
include histidine-rich glycoprotein (HRG), PF4, fibronectin, vitronectin, and vWF 
(Lijnen HR, 1983). Heparin chains of varying MW exhibit different binding capacities 
reflected in varying pharmacokinetic behaviour, with shorter heparin chains exhibiting 
a higher and more reliable bioavailability and slower clearance than larger chains. 
Heparin exhibits complex pharmacokinetics, and its anticoagulant effect is not linearly 
related to the dose. The half-life of heparin anticoagulant activity is approximately 1 
hour at therapeutic doses; it increases from 30 minutes following an intravenous bolus 
dose of 25U/kg to 150 minutes following a dose of 400U/kg. Heparin is cleared by two 
mechanisms. The rapid, saturable phase of elimination is due to receptor-mediated 
internalization of heparin by endothelial cells and macrophages of reticuloendothelial 
system (de Swart CA, 1982), while a slower nonsaturable renal mechanism is also 
operative. Heparin is excreted in the urine, mainly as metabolites, although after large 
doses up to 50% may be excreted unchanged (Estes JW. 1980; Kandrotas RJ.1992). 
Accumulation of UFH is modest in severe renal deficiency in contrast to LMWH. 
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1.3.1.3. Limitations of Unfractionated heparin therapy 
 
Unfractionated heparin has several limitations: 
1. Nonhemorrhagic limitations are caused by the AT-3-independent binding of UFH 
to (plasma proteins, thrombocytes proteins, endothelium, and macrophages) and 
charge-dependent binding properties of UFH to proteins and surfaces. 
 Pharmacokinetic limitations are caused by the AT-3-independent binding of 
heparin to plasma proteins, (Young E, 1994) to proteins released from platelets, 
(Hirsh J. 1991) and endothelial cells, which result in the variable anticoagulant 
response to heparin and to the phenomenon of heparin resistance (Granger CB, 
1996); AT-3-independent binding to macrophages and endothelial cells also 
result in the dose-dependent mechanism of clearance. 
 The biophysical limitations occur because the heparin-AT-3-complex is unable 
to inactivate factor F10a in the prothrombinase complex and thrombin bound to 
fibrin or to subendothelial surfaces. 
 The biological limitations of heparin include HIO (heparin induced osteopenia), 
HIT (heparin induced thrombocytopenia) and heparin induced skin necrosis 
(HISN). Osteopenia is caused by the binding of heparin to osteoblasts, 
(Shaughnessy SG, 1995) which then release factors that activate osteoclasts 
(HIO via interleukin 11-dependent pathway osteocalsts activation) (Rajgopal R , 
2006), whereas HIT is caused by IgG subclass, heparin-dependent antibodies. 
These antibodies bind to a conformationally modified epitope on platelet factor 
4 (PF4) (Visentin GP, 1994; Greinacher A, 1994). Simultaneous binding of 
these antibodies to Fc receptors on the platelet surface causes platelet activation. 
Activated platelets release highly prothrombotic microparticles and are then 
removed from the circulation causing thrombocytopenia. In addition, these 
activated platelets and microparticles provide a surface onto which coagulation 
factor complexes can assemble to promote thrombin generation. This 
phenomenon can then trigger venous or arterial thrombosis with venous 
thrombosis being more common (Warkentin TE, 1996). 
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2. Hemorrhagic limitations 
The non-specific binding of heparin to platelets inhibits platelet function (usually) and 
contributes to the hemorrhagic effects of heparin therapy. Platelet binding is more 
pronounced with large heparin molecules than with small heparin molecules. 
Finaly, the pharmacokinetic and non-anticoagulant biological limitations of 
unfractionated heparin are less evident with LMWH, (Hirsh J, 1992) while the limited 
affinity of the heparin-AT-3 complex to fibrin-bound thrombin and factor F10a has 
been overcome by several new classes of AT-3-independent thrombin inhibitors and 
factor F10a inhibitors (Hirsh J, 1999). 
 
 
1.3.2. Low-Molecular-Weight Heparin 
 
1.3.2.1. History of LMWHs discovery and biochemical structure 
In 1976 it was confirmed (Johnson EA, 1976; Andersson LO, 1976) that LMWH 
fractions prepared from standard heparin have been shown to have progressively less 
effect on the APTT, as they were reduced in molecular size, while still inhibiting 
activated factor F10 (factor F10a). The chemically enzymatic depolymerization of UFH 
changed the anticoagulant activity of UFH, resulting to dissociation of AT-3 dependent 
anti-factor F10a activity of UFH from its effect on thrombin (F2a) activity.  
LMWHs have reduced inhibitory activity against thrombin relative to factor F10a, 
(Harenberg J, 1990 ; Holmer E , 1981) have a more favorable benefit-to-risk ratio than 
heparin when used to treat VTE, (van Dongen CJ, 2004) and have superior 
pharmacokinetic properties (Bara L, 1988).  
LMWHs are polysulfated glycosaminoglycans that have a mean molecular weight of 4 
to 5 kDa (about 15 monosaccharide units per molecule) ranging from 2 to 9 KDa. 
Increasing anti-F10a/anti-F2a ratio of polysulfated glycosaminoglycans is directly 
proportional to the increasing in number of monosaccharide units per molecule     
(Table 3) (Lane DA, 1984). 
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  Anticoagulant Activity 
Heparin Oligosaccharides Molecular Weight Anti-10a Anti-2a 
8 2,400 1.3 - 
12 3,600 2.58 - 
16 4,800 1.60 - 
18 5,400 0.95 0.51 
24 7,200 1.30 1.21 
 
 
Table 3. Relationship between Molecular Weight and Anticoagulant Activity of 
Heparin Fractions. 
 
 
All heparin molecules contain at least 18 saccharide units; therefore unfractionated 
heparin has an anti-factor F10a/anti-factor F2a ratio of 1:1. In contrast, LMWHs have 
anti-factor F10a/anti-F2a ratios between 2:1 and 4:1, depending on their molecular size 
distribution. LMWHs are differing in their pharmacokinetic properties (binding to 
proteins and cells) and anticoagulant profiles (anti-F2a/anti-F10a ratio) and in their 
recommended dosing regimens. LMWHs have several advantages over UFH, 
including:  
1. Predictable anticoagulation dose response 
2. Improved subcutaneous bioavailability  
3. Dose-independent clearance 
4. Longer biologic half-life 
5. Lower incidence of thrombocytopenia 
6. Reduced need for routine laboratory monitoring 
LMWH such as enoxaparin are the most common used anticoagulants within hospitals 
for prophylaxis of venous thromboembolism (VTE) during surgical procedures and 
treatment patients with VTE and ACSs (Hirsh J, 2004; Laposata M, 1998; Montvale, 
NJ. 2006, Stief TW. 2007b). Enoxaparin is the sodium salt of a depolymerised heparin 
obtained by alkaline depolymerisation of the benzyl ester derivative of heparin from 
porcine intestinal mucosa. The majority of the enoxaparin components have a 4-
enopyranose uronate structure at the nonreducing end of their chain. About 20% of the 
components contain a 1,6 anhydro derivative on the reducing end of the chain. The 
molecular mass ranges between 3.8 and 5 Kda, characteristically about 4.5 Kda, the 
sulfation degree is about 2 per disaccharide unit. The chemical structure of enoxaparin 
(C26H40N2O36S5)n is illustrated in (Figure 13) 
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Figure 13. The chemical structure of enoxaparin (C26H40N2O36S5)n   
 
 
 
Pharmacokinetically, enoxaparin is rapidly and almost completely absorbed after 
subcutaneous injection with a bioavailability of about 100%. Peak plasma activity is 
reached within 1 to 5 hours. The elimination half-life is about 4 to 5 hours but               
anti-factor F10a activity persists for up to 24 hours after a 40-mg dose. Elimination is 
prolonged in patients with renal impairment. Enoxaparin is metabolised in the liver and 
excreted in the urine, as unchanged drug and metabolites. 
 
1.3.2.2. Mechanism of Action of Low-Molecular-Weight Heparin 
 
LMWHs produce their major anticoagulant effect by the potentiation of AT-3      
(Figure 14). The interaction with AT-3 is mediated by a unique specific 
pentasaccharide sequence (Choay J, 1983) which is found on less than one third of 
LMWH molecules. 
All LMWH chains containing the high-affinity pentasaccharide catalyze the 
inactivation of factor F10a. Because only pentasaccharide-containing heparin chains 
composed of at least 18 saccharide units are of sufficient length to bind AT-3 to 
thrombin, 50% to 75% of LMWH chains are too short to catalyze thrombin inhibition. 
AT-3-dependent F10a inactivation via high-affinity pentasaccharide of LMWHs does 
not require bridging between AT-3 and F10a compared to AT-3 dependent F2a 
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inactivation. Anti-factor F10a/anti-F2a ratio of LMWH is between 2:1 and 4:1, 
depending on their molecular size.  
LMWHs have a reduced ability to inactivate thrombin because the smaller fragments 
cannot bind simultaneously to AT-3 and thrombin. Reduced binding of LMWHs to 
plasma proteins is responsible for the more predictable dose-response relationship of 
LMWHs (Hirsh J, 1992). A lower incidence of binding to macrophages and endothelial 
cells increases the plasma half-life of LMWH, allowing once- or twice-daily dosing 
(Weitz JI, 1997), whereas reducing binding to PF4 and to osteoblasts may explain the 
lower incidence of HIT (heparin indused thrombocytopenia) (Warkentin TE, 1995) and 
a lower incidence HIO (heparin indused osteopenia) (Shaughnessy SG, 1995; Bhandari 
M, 1998) respectively. A comparison of LMWH with UFH is given in Table 4.  
 
 
 
 
Figure 14. Pharmacologic activity of Low-Molecular-Weight Heparins (LMWHs). 
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Property UFH LMWH Fondaparinux 
Mode of action Activation of AT-3 Activation of AT-3 Activation of AT-3 
Molecular weight, 
daltons 
3000–30,000 1500–10,000 1728 
Molecules 
containing 
high-affinity 
pentasaccharide, % 
33 33 100 
Administration IV or SC SC SC 
Plasma half-life, h 0.5–2.5 3–4 17–21 
Binding to plasma 
proteins, endothelial 
cells, platelets, and 
macrophages 
Strong Moderate No 
Dose-response Unpredictable Predictable Predictable 
Dosage Titrated to lab 
value 
Fixed dose or 
weight-based 
Fixed dose or 
weight-based 
Anti-F10a/anti-F2a 
ratio 
1.2 2–4 No anti-F2a 
activity 
APTT at therapeutic 
levels 
Prolonged Not prolonged or 
only slightly 
prolonged 
Not prolonged or 
only slightly 
prolonged 
Thrombocytopenia 
<50,000–100,000/ 
μL, incidence, % 
1.0–1.5 1.0–1.5 0 
Thrombocytopenia 
(<50,000/ μL, 
incidence, %) 
0.2 0.1 0 
HIT-2  
(immune-mediated 
thrombocytopenia), 
% 
0.1–5 < 0.1–1 None 
Bleeding 
complications, % 
3–5 Same or lower Same or lower 
Protamine reversal Effective for IV, 
less effective 
for SC 
Less effective No effective 
 
Table 4. Comparison of Unfractionated Heparin, Low-Molecular-Weight Heparin, 
and Fondaparinux. AT-3 = antithrombin; UFH = unfractionated heparin; LMWH = 
low molecular- weight heparin; IV = intravenous; SC = subcutaneous; APTT = 
activated partial thromboplastin time; HIT = heparin-induced thrombocytopenia. 
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1.4. Thrombin generation assays with use of synthetic Substrates. 
 
1.4.1. Chromogenic test system (CTS) 
 
As early s 1954 Sherry & Troll discovered the esterolytic activity of proteases and 
found that amino acid esters are very sensitive substrates for proteolytic enzymes.    
This was followed by the development of simple amino acid ester substrates (e.g. 
Tosyl-Arginin-Methyl-Ester) and chromogenic amide substrates (e.g. Benzoyl-Arginin-
p-Nitro-Anilide) (ΒΑΡΝΑ). Assuming that the cleavage of oligopeptide substrates 
reflects much more the biological activity of a protease than the cleavage of ester 
substrates or of substrates containing a single amino acid, e. g. ΒΑΡΝΑ, Blombäck & 
Svendsen were the first to synthesize chromogenic peptide substrates, e.g. Phe-Val-
Arg-pNA (S-2160), in which the chromogenic group, 4-nitroaniline, is amide-linked to 
the carboxyl group of arginine. Serine proteases hydrolyze the molecule and release 4-
Nitroaniline from this peptide. Chromogenic peptide substrates are generally composed 
of 3, sometimes also of 4 or 5 amino acids (Becker et al., 1984, Gallimore and 
Friberger, 1991). The C-terminal amino acid is often arginine, with a chromogenic 
group amide - coupled to its free carboxyl group. Today, the most currently used 
peptide substrates employ 4-nitroaniline as the chromogenic group, the release of which 
is measured at 405 nm, during the reaction in a photometer cuvette. The photometric 
measuring signal, the change in absorbance per min (ΔΑ/min), is directly proportional 
to the enzyme activity.  The CTS consists of the following reaction: 
 
Amino acid residues-pNA (chromogen) + Protease →Amino acid residues + pNA (chromophore) + Protease 
 
The CTS has several disadvantages (Mosesson et Kaminski 1990, Stief TW, 2006).  
• Nonspecific protease-substrate (thrombin-substrate), i.e. cleavage of the protease-
substrate (thrombin-substrate) by thrombin-like enzymes such as kallikrein 
• Turbidity during of clot formation with generation of antithrombin-1 = fibrin. 
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1.4.2. Fluorogenic test system (thrombin generation test; TGT) 
 
To avoid the disadvantages resulting from chromogenic test systems, thrombin activity 
was measured by a fluorogenic thrombin substrate (Hemker HC. et al. 2002; Hemker 
HC et al. 2003). Using a “slow” fluorogenic thrombin substrate and continuous 
comparison to a simultaneously run calibrator, thrombin generation can be monitored 
automatically, online, in clotting platelet-rich plasma or platelet-poor plasma, (PRP or 
PPP).  
The resulting “Calibrated Automated Thrombogram (CAT)” in PPP tries to measure 
hypocoagulability (haemophilias, oral anticoagulants, heparins, heparinoids,                
direct inhibitors) and hypercoagulabilities (AT deficiency, F2 hyperexpression,               
PC and PS deficiency,  F5Leiden, oral contraceptives) (Hemker H C. 2002). 
In PRP it is diminished in thrombopathies, in von Willebrand disease, by antibodies 
blocking GPIIb-IIIa or GPIb, or by antiplatelet drugs like aspirin and clopidogrel. 
Lupus anticoagulant increases -but unfortunately also retards- thrombin generation in 
the CAT. The thrombogram thus appears to be a broad function test of the haemostatic- 
thrombotic mechanism of blood (Hemker H C. 2002). 
 
The CAT has several disadvantages 
1. Unspecificity due to contact-phase activation of coagulation (multi-talented 
kallikrein splits all kind of chromogenic substrates) 
2. Dependence on antithrombin-1 (fibrin), an in vitro test phenomenon that is of minor 
in vivo importance 
3. Generated fibrin leads to renewed activation of coagulation 
4. Long processing time 
5. Calibration in nM  
6. Internal filter effect 
7. Necessity of special equipment 
8. Instability of thrombin-alpha2macroglobulin complexes 
9. Overestimation of thrombin activities > 1 IU/ml, underestimation of clinically 
relevant thrombin activities < 0.1 IU/ml. 
10. Expensive 
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2. Objective 
 
Low-molecular-weight heparin (LMWH) is the most important anticoagulant inside 
hospitals. There might be great inter-individual variation of the plasma response to a 
certain LMWH dosage. The present work quantifies this inter-individual variation using 
the best thrombin generation tests internationally available. 
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3. Material and Methods 
 
 
 
3.1. Arginine 
Important for the performance of Recalcified Coagulation Activity Assay (RECA) and 
Extrinsic Coagulation Activity Assay (EXCA) was the discovery of the serine protease 
inhibitory properties of arginine (Dano and Reich, 1979). Most of the coagulation 
factors, except protein S, in their active form are serine proteases (Girolami A et al 
2008; Stafford DW 2005; Nelsestuen GL et al. 2000) that interact with their target-
substrats often involves arginine residue in the P1 position. Arginine is an amino acid 
of the P1-P1´ reactive center of many serpins (Stief T W. 2007c; Gettins PG. 2002). 
Arginine or guanidine inhibits serine proteases (Stief et.al. 2001). The proteinolytic 
activity of thrombin, plasmin, and C1-esterase is inhibited by arginine (Stief TW. 
2007c). Arginine inhibited the Whole blood clotting time (WBCT), PT, APTT, in vitro 
bleeding test closure time (IVBT-CT), and whole blood aggregometry (WBA) (Stief T 
W. 2007c). Arginine resulted in a two-fold prolongation of WBCT, PT, or IVBT-CT 
(the anti-epinephrine action is superior to the anti-ADP action), a four-fold 
prolongation of APTT or a 60% inhibition of WBA (Stief T W. 2007c).   
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3.2. Recalcified Coagulation Activity Assay (RECA) 
3.2.1. Reagents 
•Polypropylene monovettes containing 0.5 ml 106 mM sodium citrate,                     
(Sarstedt, Nümbrecht, Germany) 
•Untreated F-well polystyrene plates (NUNC, Wiesbaden, Germany, article nr. 446140) 
•Bovine thrombin (Siemens Healthcare, Munich, Germany; article no. B 4233-25,                 
130 IU/vial) 1 IU/ml  in 6.7% of human albumin (Kabi, Stockholm, Sweden) 
•Siliconized glass bottles (Siemens Healthcare, Munich, Germany; article nr. OVKE49) 
•Multipette (Eppendorf AG, Hamburg, Germany) 
•Unfractionated Heparin (ratiopharm, Ulm, Germany) in siliconized glass bottles 
•LMWH enoxaparin (Aventis, Frankfurt, Germany) in siliconized glass bottles  
•CaCl2 (Sigma, Deisenhofen, Germany) 250 mM in siliconized glass bottles 
• Digitally controlled water bath (37°C) (Memmert, Schwabach, Germany) 
•Arginine, 2.5 M, pH 8.6, 0.16% Triton X 100® (Sigma) 
•Chromogenic thrombin substrate cyclohexylglycyl-alanyl-arginyl-para-nitroanilide 
(CHG-Ala-Arg-pNA) (Pentapharm, Basel, Switzerland; article no. 081-20),                  
1 mM in 1.25 M arginine, pH 8.7 
•Microtiter plate photometer (Milenia- DPC, Los Angeles, USA) 
 
 
 
3.2.2. Test performance of Recalcified Coagulation Activity Assay (RECA) 
Citrated blood (0.5 ml 106 mM sodium citrate + 4.5 ml venous blood) of healthy 
donors after thankful written informed consent was centrifuged within 2 h (23oC) at 
2800g for 10 min (23oC). In the recalcified coagulation activity assay (RECA) 50 μl 
normal plasma or patient plasma (for routine quality assurance of plasmatic F2a activity 
determinations taken out of the routine waste) were pipetted in duplicate by an 
Eppendorf-Multipette® with 0.9 % NaCl-rinsed and completely emptied new 
polypropylene tips into polystyrene F-well microtiterplates. 2 μl 0-260 mlU/ml 
unfractionated heparin in 0.9 % NaCl or 2 μl 0-260 mlU/ml LMWH enoxaparin in     
0.9 % NaCl were added to generate final anticoagulant concentrations of 0, 0.1, 1, and 
10 mIU/ml, starting with the lowest concentration. The plates were intensely shaken for 
10s. After 10 min (23oC) 5 μl 250 mM CaCl2 were added. After intense shaking for 
10s, the plates were brought into a 37oC digitally controlled water-bath. After 40 min 
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(main value) or 45 min (control value) at 37oC, 100 μl 2.5 M arginine, pH 8.6, 0.16 % 
Triton X 100® were added. After 3 min 25 μl 1 mM chromogenic thrombin substrate 
CHG-Ala-Arg-pNA in 1.25 M arginine, pH 8.7, were added, and the linear increase of 
absorbance with time at 23oC (∆A/t) was measured (linear range: up to 40 % of 
maximal ∆A (900 mA). The results were standardized against 1 IU/ml bovine thrombin 
in 6.7% human albumin that replaced the plasma sample and resulted in about 160 
mA/min (23oC). The basal thrombin activity in citrated plasma prior to any CRT was 
also determined; this about 10 mIU/ml basal thrombin activity was substracted from all 
thrombin activities measured in RECA. The plasmas were analyzed in the RECA with a 
coagulation reaction time (CRT) of 40 min (37oC) (RECA-40). 40 min reaction time 
was chosen for these lots of polyproplene blood sampling tubes and of microwells 
because at 40 min CRT the thrombin generation was still ascending, i.e. the ratio 
between thrombin activity at 40 min CRT and thrombin activity at 45 min CRT in 
unsupplemented plasmas was less than 1. 
  
 
 
 
 
 
 
3.3. Extrinsic Coagulation Activity Assay (EXCA)  
 
3.3.1. Reagents   
 
•Untreated polystyrene microtiterplates with round bottom U-wells (Greiner, 
Frickenhausen, Germany; article nr. 650161, lot nr. 05281161) 
•TF-reagent; 1 ml aliquots of once frozen/thawed 1 ng/ml tissue factor without 
polybrene® (Thromborel S®, Behringwerke, Marburg, Germany), 250 mM CaCl2, 5% 
human albumin (Kabi, Stockholm, Sweden) in siliconized 15 ml glass vials                
(Stief TW et al. 2008a) 
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3.3.2. APTT and EXCA in pooled normal plasma  
 
500 μl samples of unfrozen pooled normal plasma were supplemented with 20 μl         
0-26 IU/ml unfractionated heparin in 0.9 % NaCl or with 20 μl 0-26 IU/ml of the                        
LMWH enoxaparin in 0.9 % NaCl. After 90 min at 23oC the samples were assayed for 
APTT (Pathromtin SL, Behring Coagulation Timer (BCT), DadeBehring, Marburg, 
Germany). The control value was that of 0 IU/ml drug. At the same time point, these 
samples were also analyzed in the EXCA: 50 μl plasma in polystyrene  U-wells were 
activated after  90 min preincubation at 23oC with 5 μl TF-reagent that was added by an 
Eppendorf-Multipette® with 0.9% NaCl-rinsed polypropylene-tips.  After intense 
shaking for 5s, the plates were brought into a 37oC digitally controlled water-bath. 
After 1 min or 2 min at 37oC, the plates were taken out of the water bath and 100 μl 2.5 
M arginine, pH 8.6, 0.16% Triton X 100® were added. The coagulation reaction time 
(CRT) of  1 min (37oC) is the main value =EXCA-1, the CRT of 2 min is the control 
value =EXCA-2 (EXCA-1/EXCA-2 ration was always < 1, i.e. thrombin generation at  
1 min CRT was always in the increasing part of the thrombin generation curve).  After 
3 min at 23oC, 25 μl 1 mM chromogenic thrombin substrate cyclohexylglycyl-alanyl-
arginyl-para-nitroanilid (CHG-Ala-Arg-pNA) in 1.25 M arginine, pH 8.7, were added, 
and the linear increase of absorbance with time at 23oC (ΔA/t) was measured (linear 
range: up to 40 % of maximal ΔA, which is about 1050 mA) by a microtiter plate 
photometer with a 1 mA resolution. The results were standardized with 1 IU/ml bovine 
thrombin (DadeBehring) in 6.7 % human albumin that replaced the plasma sample, and 
resulted in about 16 mA/min (23oC). The basal thrombin activity in citrated plasma 
prior to any CRT was also determined by first addition of the arginine-reagent and then 
addition of the TF-reagent. This basal thrombin activity was substracted from all 
thrombin activities measured in EXCA, transforming the thrombin activities into 
thrombin generations. The basal thrombin activity in citrated patient plasmas was 
8.0±2.4 mIU/ml (100±30%). The basal thrombin activity in citrated plasmas of healthy 
donors was 7.3±2.0 mIU/ml (100±27%). Since the basal thrombin activity in pooled 
normal EDTA-plasma is 5.5 mIU/ml (Stief TW, 2006), hemostasis in the citrated 
samples was only minimally pre-activated.   
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3.3.3. Extrinsic Coagulation Activity Assay (EXCA) in normal plasma and patient 
plasma 
 
Citrated blood (0.5 ml 106 mM sodium citrate + 4.5 ml venous blood in polypropylene 
monovettes) of healthy donors after thankful written informed consent was centrifuged 
at 2800g for 10 min (23oC). 50 µl normal plasma or patient plasma for routine quality 
assurance of chromogenic F2a determinations taken out of the routine waste were 
analyzed in duplicate in the extrinsic coagulation activity assay (EXCA): 50 μl samples 
were pipetted with an  Eppendorf-multipette® with 0.9 % NaCl-rinsed and completely 
emptied new polypropylene tips into polystyrol microwells with round bottom  (U-
wells; Greiner)  2 μl 0- 26 IU/ml unfractionated heparin in 0.9 % NaCl or 2 μl   0-26 
IU/ml enoxaparin in 0.9% NaCl were added to generate final anticoagulant 
concentrations of 0, 0.01, 0.1, 0.2, 0.5, and 1 IU/ml, starting with the lowest 
concentration. After intense shaking for 5s, the plates were brought into a 37oC digitally 
controlled water-bath. After 1min or 2 min at 37oC, the plates were taken out of the 
water bath and 100 μl 2.5 M arginine, pH 8.6, 0.16 % Triton X 100® were added. The 
coagulation reaction time (CRT) of 1 min (37oC) is the main value =EXCA-1, the CRT 
of 2 min is the control value =EXCA-2 (EXCA-1/EXCA-2 ration was always < 1, i.e. 
thrombin generation at 1min CRT was always in the increasing part of the thrombin 
generation curve). After 3 min at 23oC, 25 μl 1 mM chromogenic thrombin substrate 
cyclohexylglycyl-alanyl-arginyl-para-nitroanilide  (CHG-Ala-Arg-pNA) in 1.25 M 
arginine, pH 8.7, were added, and the linear increase of absorbance with time at 23oC 
(ΔA/t) was measured (linear range  up to 40 % of maximal ΔA = about 1050 mA) by a 
microtiter plate photometer with a 1 mA resolution. The results were standardized with 
1 IU/ml bovine thrombin (DadeBehring) in 6.7 % human albumin that replaced the 
plasma sample, and resulted in about 16 mA/min (23oC). The basal thrombin activity in 
citrated plasma prior to any CRT was also determined by first addition of the arginine 
reagent and then addition of the tissue factor reagent. This basal thrombin activity was 
substracted from all thrombin activities measured, transforming thrombin activities into 
thrombin generations.  
 
 
 
 
Results                                               The Plasma Sensibility to Heparin and Enoxaparin 
______________________________________________________________________ 
 54 
4. Results 
4.1. Individual anticoagulant efficiency of heparin and of the 
LMWH enoxaparin 
4.1.1- LMWH (enoxaprin) and unfractionated heparin in APTT and EXCA.  
Unfrozen pooled normal plasma was supplemented with heparin or with the                     
low-molecular-weight-heparin (LMWH) enoxaparin. After preincubation time of               
90 min at 23°C the samples were assayed simultaneously for APTT and extrinsic 
coagulation activity assay (EXCA).  
Figure 4.1.1a demonstrates that 0.5 IU/ml enoxaparin prolonged the APTT of pooled 
normal plasma from 29s to about 40s; the same prolongation of APTT is noted by only 
0.1 IU/ml unfractionated heparin.  
Normal APTT control (0 IU/ml drug concentration) = 29s. The 1.5fold prolongation of 
the normal APTT control (43s) is reached at 0.11 IU/ml heparin, 2fold prolongation of 
the normal APTT control (58s) is reached at 0.15 IU/ml heparin and 3fold prolongation 
of the normal APTT control (87s) is caused by 0.25 IU/ml heparin. 
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Figure 4.1.1a. APTT in pooled normal plasma. Unfrozen pooled normal plasma was 
supplemented with heparin () or with the low-molecular-weight-heparin (LMWH) 
enoxaparin (●).  
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Figure 4.1.1b demonstrates that 0.11 IU/ml, 0.15 IU/ml, or 0.25 IU/ml heparin 
corresponded to about 40 %, 20 %, or 10 % of normal thrombin generation in the 
EXCA, respectively.  
100 % EXCA = generation of 46223 mIU/ml (mean value  1 standard deviation) 
thrombin (F2a) within 1 min (37°C) in unsupplemented controls.  
1.5 fold (43s) prolongation of the normal APTT corresponded to about 40 % EXCA, 
2fold (58s) prolongation of the normal APTT corresponded to about 20 % EXCA and 
3fold (87s) prolongation of the normal APTT corresponded to about 10 % EXCA. 
The slightest prophylactic anticoagulation, equivalent to about 40 % of normal EXCA, 
occurred at about 0.3 IU/ml (LMWH) enoxaparin concentration. The therapeutic 
anticoagulation, equivalent to about 10-20 % of normal EXCA, occurred at about 0.6 
IU/ml - 1 IU/ml (LMWH) enoxaparin concentration (Fig. 4.1.1b). 
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Figure 4.1.1b. EXCA in pooled normal citrated plasma. EXCA values of the same 
samples of Figure 4.1.1a (heparin (), enoxaparin (●)). 
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4.1.2. Thrombin generation in EXCA [mIU/ml] at different supplementations of 
heparin or enoxaparin in normal citrated plasmas. 
Citrated plasma samples of normal healthy donors (n=51) were supplemented with 
unfractionated heparin or with low-molecular-weight-heparin (LMWH) enoxaparin. 
The EXCA was performed (main value = 1 min incubation at 37°C = EXCA-1). 
Mean values were defined a percent of thrombin generation in EXCA by 
unsupplemented citrated plasma control [% of unsupplemented citrated plasma 
control]. 
Thrombin generation in EXCA at 0 IU/ml heparin was 423127 mIU/ml = 100 % F2a 
generation, at 0 IU/ml LMWH it was 35896 mIU/ml. 
 
Figure 4.1.2a demonstrated that the mean approximate 50 % inhibitory concentration 
(IC50) of unfractionated heparin was 0.08 IU/ml; the mean IC50 of low-molecular-
weight-heparin (LMWH) enoxaparin was 0.14 IU/ml. 
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Figure 4.1.2a. EXCA inhibition by heparin and (LMWH) enoxaparin in normal 
citrated plasmas (of n=51 healthy donors). Supplementation with heparin () or 
with enoxaparin (●). 
 
 
0.01 IU/ml low-molecular-weight-heparin (LMWH) enoxaparin or 0.01 IU/ml heparin 
decreased the normal thrombin generation in EXCA by about 17 % and   9 %, 
respectively.  
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1 IU/ml (LMWH) enoxaparin concentration reduced the normal thrombin generation in 
EXCA to about 13 % of normal whereas at 1 IU/ml heparin the normal thrombin 
generation in EXCA was completely suppressed. This means that 1 IU/ml LMWH is 
strongly therapeutic, but 1 IU/ml heparin is in the toxic range. 
 
0.1 IU/ml heparin in individual normal citrated plasmas resulted in a thrombin 
generation of 4316 % of the unsupplemented plasma control. A thrombin generation 
of more than 59 % of normal indicated plasmatic resistance against 0.1 IU/ml heparin, a 
thrombin generation of less than 27 % of normal indicated plasmatic hyper-
responsiveness to 0.1 IU/ml heparin (Fig. 4.1.2b). There was nearly no correlation 
(r=0.227) between normal thrombin generation in EXCA [mIU/ml] at 0 IU/ml heparin 
and thrombin generation in EXCA [% of unsupplemented citrated plasma control] at 
0.1 IU/ml heparin in plasma. 
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Figure 4.1.2b. Thrombin generation in normal citrated plasmas with 0 IU/ml or 
with 0.1 IU/ml heparin.  
 
0.1 IU/ml LMWH-enoxaparin in individual normal citrated plasmas resulted in a 
thrombin generation of 5712 % of the unsupplemented plasma control. A thrombin 
generation of more than 69 % of normal indicated plasmatic resistance against           
0.1 IU/ml LMWH-enoxaparin, a thrombin generation of less than 45 % of normal 
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indicated plasmatic hyper-responsiveness to 0.1 IU/ml LMWH-enoxaparin (Fig. 
4.1.2c). There is no correlation (r=0.026) between normal thrombin generation in 
EXCA [mIU/ml] by supplementation with 0 IU/ml LMWH-enoxaparin concentration 
and thrombin generation in EXCA [% of unsupplemented citrat-plasma control] at 0.1 
IU/ml enoxaparin concentration. 
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Figure 4.1.2c. Thrombin generation in normal citrated plasmas with 0 IU/ml or 
with 0.1 IU/ml LMWH-enoxaparin.  
 
 
A comparison between normal thrombin generation in EXCA at 0.1 IU/ml heparin 
concentration and normal thrombin generation in EXCA at 0.1 IU/ml LMWH-
enoxaparin concentration had only a slight correlation (r=0.334) (Fig. 4.1. 2d), i.e. the 
response of patients against unfractionated heparin or LMWH-enoxaparin might be 
completely individually different.  
0.2 IU/ml enoxaparin resulted in 4211 %, 0.5 IU/ml enoxaparin in 2110 %, and             
1 IU/ml in 137 % of normal F2a generation. The respective values for heparin were 
1610 %, 64 %, and 23 %. 
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Figure 4.1.2d. Thrombin generation in normal citrated plasmas with 0.1 IU/ml 
heparin or with 0.1 IU/ml LMWH.  
 
 
4.1.3. Thrombin generation in EXCA [mIU/ml] at different supplementations of 
heparin or of enoxaparin in patient plasmas. 
Citrated plasma samples of patients (n=213) without anticoagulation therapy and with 
normal hemostatic parameters (PT, APTT) were supplemented with unfractionated 
heparin or with low-molecular-weight-heparin (LMWH) enoxaparin. 
The EXCA was performed (main value = 1 min incubation at 37°C = EXCA-1). 
Thrombin generation in EXCA at 0 IU/ml heparin supplementation and at 0 IU/ml 
LMWH-enoxaparin were 708341 mIU/ml = 100 % F2a generation, 643340 mIU/ml 
= 100 % F2a generation respectively. 
Figure 4.1.3a demonstrated that the mean approximate 50 % inhibitory concentration 
(IC50) of unfractionated heparin was 0.09 IU/ml; the mean IC50 of low-molecular-
weight-heparin (LMWH) enoxaparin was 0.16 IU/ml. 
Results                                               The Plasma Sensibility to Heparin and Enoxaparin 
______________________________________________________________________ 
 60 
0
10
20
30
40
50
60
70
80
90
100
0 0,1 0,2 0,3 0,4 0,5 0,6 0,7 0,8 0,9 1
Drug concentration [IU/ml]
II
a
 G
e
n
e
ra
ti
o
n
 i
n
 E
X
C
A
 [
%
 c
o
n
tr
o
l]
 
Figure 4.1.3a. EXCA inhibition by heparin and (LMWH) enoxaparin in citrated 
patient plasmas (of n=213 patients without anicoagulants and with normal 
hemostasis). Supplementation with heparin () or with enoxaparin (●). 
 
 
Mean values of anticoagulant efficiency of 0.01 IU/ml concentration LMWH-
enoxaparin and 0.01 IU/ml concentration unfractionated heparin were 84 % and 93 % 
respectively. The Comparison of mean values demonstrated that anticoagulat efficiency 
of 0.01 IU/ml enoxaparin was superior to 0.01 IU/ml heparin with high statistic 
significance (χ2corr = 8.58, p< 0.01).  
0.1 IU/ml heparin in individual patient citrated plasmas resulted in a thrombin 
generation of 4614 % of the unsupplemented plasma control. A thrombin generation 
more than 60 % of normal indicated plasmatic resistance against 0.1 IU/ml heparin;             
a thrombin generation less than 32 % of normal indicated plasmatic hyper-
responsiveness to 0.1 IU/ml heparin (Fig. 4.1.3b). There was nearly no correlation 
(r=0.163) between normal thrombin generation in EXCA [mIU/ml] by supplementation 
with 0 IU/ml heparin concentration and thrombin generation in EXCA [% of 
unsupplemented citrated plasma control] at 0.1 IU/ml heparin concentration             
(Fig. 4.1.3b).  The higher F2a generation [mIU/ml] in citrated plasma samples of 
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patients when compared to that in citrated plasma samples of normal healthy donors 
might be attributed to  
1. Pre-analytic differences (longer pre-analytic time interval till analysis, the patient 
samples were taken out of the routine waste),  
2. Some procoagulant tendencies in blood of patients when compared with healthy 
donors. 
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F
igure 4.1.3b. Thrombin generation in patient plasmas supplemented with                  
0 IU/ml or with 0.1 IU/ml heparin.  
 
 
0.2 IU/ml LMWH-enoxaparin in individual patient citrated plasmas resulted in a 
thrombin generation of 4713 % of the unsupplemented plasma control. A thrombin 
generation more than 60 % of normal control indicated plasmatic resistance against 0.2 
IU/ml LMWH-enoxaparin, a thrombin generation less than 34 % of normal control 
indicated plasmatic hyper-responsiveness to 0.2 IU/ml LMWH-enoxaparin (Fig. 
4.1.3c). There was no correlation (r= 0.049) between normal thrombin generation in 
EXCA [mIU/ml] by supplementation with 0 IU/ml LMWH-enoxaparin concentration 
and thrombin generation in EXCA [% of unsupplemented citrat-plasma control] at 0.2 
IU/ml LMWH-enoxaparin concentration. 
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Figure 4.1.3c. Thrombin generation in patient plasmas supplemented with                    
0 IU/ml or with 0.2 IU/ml LMWH.  
 
But there was slight correlation (r=0.262) between normal thrombin generation in 
EXCA [mIU/ml] by supplementation with 0.1 IU/ml unfractionated heparin 
concentration and thrombin generation in EXCA [% of unsupplemented citrat-plasma 
control] at 0.2 IU/ml LMWH-enoxaparin concentration (Fig. 4.1.3d). 
The response of individual patients to enoxaparin when compared to heparin seems to 
be better predictable. 
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Figure 4.1.3d. Thrombin generation in normal citrated plasmas supplemented 
with 0.1 IU/ml heparin or with 0.2 IU/ml LMWH-enoxaparin 
 
0.2 IU/ml enoxaparin resulted in 4713 %, 0.5 IU/ml enoxaparin in 2811 %, and              
1 IU/ml in 129 % of normal F2a generation. The respective values for heparin were 
199 %, 75 %, and 23 % (greater standard deviation). The results in percent of 
thrombin generations of unsupplemented patient citrated plasma were similar to the 
results in precent of the thrombin generations of unsupplemented normal healthy donor 
citrated plasma. 
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4.2. Comparison of routine parameters (APTT, INR, CRP, 
Fibrinogen, Thrombocytes) with EXCA 
The EXCA-1 values [% of unsupplemented citrat-plasma control] in citrated plasma 
samples of patients (n=213) after supplementation with heparins (heparin, enoxaparin)  
at approximatly 50 % inhibitory concentration (IC50) were compared with the routinely 
measured hemostatic parameters values APTT, INR, Fibrinogen concentration, platelets 
count, and C reactive protein (CRP). 
 
4.2.1. Comparison of EXCA-1 with APTT  
APTT (Pathromtin SL®; Behring Coagulation Timer (BCT) DadeBehring)  (31.43.3s) 
and EXCA-1 results in the n=213 samples of patients of Fig. 4.1.3a after 
supplementation with 0.1 IU/ml heparin had no correlation, r= -0.072 (Figure 4.2.1.). 
APTT (31.43.3s) and EXCA-1 values in the n=213 samples of patients of                        
Fig. 4.1.3a after supplementation with 0.2 IU/ml LMWH-enoxaparin did not correlate, 
too (r= 0.023).   
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Figure 4.2.1. APTT and thrombin generation in patient plasmas after 
supplementation with heparin (●) or enoxaparin (o). 
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4.2.2. Comparison of EXCA-1 with international normalized ratio (INR)   
INR (Thromborel S®) (1.020.07) and EXCA-1 values in the n=213 samples of 
patients of Fig. 4.1.3a after supplementation with 0.1 IU/ml heparin had no correlation, 
r= -0.045 (Fig. 4.2.2.) 
INR (1.020.07) and EXCA-1 results in the n=213 samples of patients of Fig. 4.1.3a 
after supplementation with 0.2 IU/ml LMWH-enoxaparin also had no correlation              
(r=- 0.101). 
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Figure 4.2.2. INR and thrombin generation in patient plasmas after 
supplementation with heparin (●) or enoxaparin (o). 
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4.2.3. Comparison EXCA-1 with functional fibrinogen concentration 
Fibrinogen concentration (modified Clauss-Method; BCT; DadeBehring) (3.71.4 g/l) 
and EXCA-1 values in the n=213 samples of patients of Fig. 4.1.3a after 
supplementation with 0.1 IU/ml heparin did not correlate, r= 0.157 (Fig. 4.2.3.) 
Fibrinogen concentration (3.71.4 g/l) and EXCA-1 values in the n=213 samples of 
patients of Fig. 4.1.3a after supplementation with 0.2 IU/ml LMWH-enoxaparin also 
did not correlate (r=- 0.003).   
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Figure 4.2.3. Fibrinogen concentration and thrombin generation in patient 
plasmas after supplementation with heparin (●) or enoxaparin (o). 
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4.2.4. Comparison EXCA-1 with C reactive protein   
 
Samples with CRP values < 5 mg/l were pooled; the pool was analyzed with an ultra-
sensitive assay for CRP, resulting in 2 mg/l CRP. All CRP results < 5 mg/l were 
attributed to 2 mg/l. 
C - reactive protein concentration (CRP; Beckman, Krefeld, Germany) (9.725.9 mg/l) 
and EXCA-1 values in the n=213 samples of patients of Fig. 4.1.3a after 
supplementation with 0.1 IU/ml heparin had no correlation, r= 0.118 (Fig. 4.2.4).   
C - reactive protein concentrations (9.725.9 mg/l) and EXCA-1 results in the n=213 
samples of patients of Fig. 4.1.3a after supplementation with 0.2 IU/ml LMWH-
enoxaparin did not correlate, too ( r=- 0.130).    
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Figure 4.2.4. C - reactive protein (CRP mg/l) concentration and thrombin 
generation in patient plasmas after supplementation with heparin (●) or 
enoxaparin (o). 
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4.2.5. Comparison of EXCA-1 values with platelets count  
The platelets count (SysmexXE2100, Hamburg, Germany) (24000070000/µl) and the 
EXCA-1 values in the n=167 samples of patients of Fig. 4.1.3a after supplementation 
with 0.1 IU/ml heparin (4615%) had no correlation, r= 0.095.  
The platelets count (240.00070.000/µl) and the EXCA-1 results in the n=167 samples 
of patients of Fig. 4.1.3a after supplementation with 0.2 IU/ml LMWH-enoxaparin 
(4713%) did not correlate, r=- 0.299.  
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Figure 4.2.5. Count of thrombocytes and thrombin generation in patient plasmas 
after supplementation with heparin (●) or enoxaparin (o). 
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4.3. Loss of anticoagulant action by ultra-low dose heparin 
4.3.1. No anticoagulant action of ultra-low dose heparin, pronounced 
anticoagulant action of ultra-low dose enoxaparin in normal plasmas 
 
RECA-40 in citrated plasma (50 µl) samples of healthy donors (n=10) demonstrated 
that heparin lost anticoagulant action at ultra-low concentrations, whereas at the same 
concentration enoxaparin did act as an anticoagulant. 
 
Citrated plasma (50 µl) of healthy donors (n=10; each donor has an individual symbol) 
in flat bottomed polystyrene microtiterplates were supplemented with gradually 
increasing concentrations of unfractionated heparin (0-10 mIU/ml) or with gradually 
increasing concentrations low-molecular-weight-heparin (LMWH) enoxaparin (0-10 
mIU/ml). 
The recalcified coagulation activity assay with a coagulation reaction time (CRT) of 40 
min (37°C) (RECA-40) was performed and and ∆A/t was measured. 
Thrombin generation in RECA-40 at supplementation with 0 IU/ml heparin 
concentration and at 0 IU/ml LMWH-enoxaparin are 325250 mIU/ml = 100 % 
thrombin generation, 295180 mIU/ml = 100 % thrombin generation respectively. 
Figure 4.3.1a / Figure 4.3.1b demonstrate that unfractionated heparin or LMWH-
enoxaparin reduced thrombin generations in RECA-40 more than 50% at final plasma 
concentration more than 1 mIU/ml in citrated plasma of healthy donors.                             
At 0.1 mIU/ml heparin does not reduce thrombin generation in RECA-40; instead it 
even increased the thrombin generation in RECA-40 by some 20 %, whereas                     
0.1 mIU/ml enoxaparin significantly decreased thrombin generation in RECA-40 by 
about 30 %. 
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Figure 4.3.1a Inhibition of RECA-40 by increasing concentrations of 
unfractionated heparin (0-10 mIU/ml) in citrated plasma (50 µl) of healthy donors 
(n=10; each plasma has an individual symbol). 
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Figure 4.3.1b Inhibition of RECA-40 by increasing concentrations of LMWH-
enoxaparin (0-10 mIU/ml) in citrated plasma (50 µl) of healthy donors (n=10; each 
plasma has an individual symbol). 
Decreasing thrombin generation in RECA-40 at final concentrations of unfractionated 
heparin of 10 mIU/ml when compared to that of LMWH-enoxaparin at same final 
concentration demonstrated that heparin at this concentration was a stronger 
anticoagulant than enoxaparin (Figure 4.3.1c)    
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Figure 4.3.1c Inhibition of mean values in RECA-40 by increasing concentrations 
of heparin () (0-10 mIU/ml) or enoxaparin (●) (0-10 mIU/ml) in 50 µl normal 
citrated plasma. 
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4.3.2. Slight anticoagulant action of heparin, pronounced anticoagulant action of 
enoxaparin, both at ultra-low concentrations 
 
RECA-40 in citrated plasma (50 µl) samples of patients (n=32) demonstrated that 
heparin slightly (10%) reduced thrombin generation at ultra-low concentrations, 
whereas at the same concentration enoxaparin significantly reduced it (55%). 
 
Citrated plasma (50 µl) samples of patients (n=32; each patient has an individual 
symbol) without anticoagulation therapy and with normal hemostatic parameters  (PT, 
APTT) were supplemented with gradually increasing concentrations of unfractionated 
heparin (0-10 mIU/ml) or with gradually increasing concentrations low-molecular-
weight-heparin (LMWH) enoxaparin (0-10 mIU/ml). 
The recalcified coagulation activity assay with a coagulation reaction time (CRT) of 40 
min (37°C) (RECA-40) was performed and ∆A/t was measured. 
Thrombin generation in RECA-40 at supplementation with 0 IU/ml heparin 
concentration and at 0 IU/ml LMWH-enoxaparin were 449239 mIU/ml = 100 % 
thrombin generation, 413227 mIU/ml = 100 % thrombin generation respectively. 
Figure 4.3.2a / Figure 4.3.2b showed that 0.1 mIU/ml concentration of unfractionated 
heparin or 0.1 mIU/ml concentration of LMWH-enoxaparin decreased thrombin 
generation in RECA-40 by 10%, 55% respectively, whereas at 10 mIU/ml 
anticoagulant heparin was at least as efficient as enoxaparin. 
 
The slight differences between Fig.4.3.1c and 4.3.2c might be due to  
1. different storage time of medical student samples and patient samples (taken out of 
routine waste), which might result in different generation of procoagulant 
microparticles (Sinauridze EI. 2007), 
2. different lots of polypropylene blood tubes with polypropylene tops, that might 
contain different amounts of pro-or anti-heparinic plastic material (Stief TW. 2008b), 
3. different lots of polystyrene microtiter plates, which might also contain different 
amounts of pro- or anti-heparinic plastic material, especially if the plates are gamma-
irradiated (Stief TW. 2006). 
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Figure 4.3.2a Inhibition of RECA-40 by increasing concentrations of 
unfractionated heparin (0-2 mIU/ml) in citrated patient plasmas (50 µl; n=32; each 
plasma has an individual symbol). 
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Figure 4.3.2b inhibition of RECA-40 by increasing concentrations of LMWH-
enoxaparin (0-2 mIU/ml) in citrated patient plasmas (50 µl; n=32; each plasma has 
an individual symbol). 
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Figure 4.3.2c Inhibition of mean values in RECA-40 by increasing concentrations 
of heparin () (0-10 mIU/ml) or enoxaparin (●) (0-10 mIU/ml) in 50 µl citrated 
patient plasmas. 
 
 
Discussion                                         The Plasma Sensibility to Heparin and Enoxaparin 
______________________________________________________________________ 
 75 
5. Discussion 
 
The estimated total number of symptomatic VTE (Venous thromboembolism) events 
per annum within the six EU countries (France, Germany, Italy, Spain, Sweden, United 
Kingdom) was 466,000 cases of deep-vein thrombosis (DVT), 296,000 cases of 
pulmonary embolism (PE), and 370,000 VTE-related deaths. Of these deaths,              
an estimated 7% were diagnosed as being antemortem; 34% were sudden fatal PE, and 
59% followed undiagnosed PE. (Cohen et al. 2007). 
Acute coronary syndromes (ACSs) are traditionally divided into two separate 
categories based on the presenting electrocardiogram ECG: STMI (ST segment 
elevation >0.1 mV in all leads other than V2-V3; for leads V2-V3 ≥0.2 mV in men ≥40 
years, ≥0.25 mV in men <40 years, or ≥0.15 mV in women) and NSTMI 
(ESC/ACCF/AHA/WHF committee). By patients with STMI a 1% absolute decrease in 
mortality was observed for each hour of decreasing time to treatment (Dalen JE, 1988). 
Ratio mortality in STMI-patients treated within 70 minutes from onset of symptoms 
when compared to that of those treated between 70 minutes and 3 hours was 1.2%, 
8.7% respectively (Weaver; 1993). Most of patients with VTE or ACSs events initially 
have been either treated or prevented with the traditional anticoagulants subcutaneously 
or intravenously unfractionated heparin (UFH) or with low-molecular-weight-heparin 
(LMWHs) subcutaneously such as enoxaparin, a most common used anticoagulants for 
patients within hospitals. 
The anticoagulant potency or activity of unfractionated heparin can be measured by the 
activated partial thromboplastin time (APTT), however the effects of LMWHs cannot 
be acceptably measured using the activated partial thromboplastin time (APTT).  The 
aim of the present work was to measure of sensibility of individual plasma to 
unfractionated heparin (UFH) or low-molecular-weight-heparin (LMWH) enoxaparin 
using extrinsic coagulation activity assay (EXCA), a new chromogenic thrombin 
generation assaye for measurement of anticoagulation efficiency of UFH and LMWHs. 
Anticoagulants (UFH, LMWH) in this present research were added to citrated plasma 
directly out of a siliconized original vial to obtain the final plasma concentration 
without further plasma dilution steps, which imitates the continuous intravenously 
infusion or the subcutaneous administration of these anticoagulants. 
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The results of present study show that the slightest prophylactic anticoagulation, 
equivalent to about 40 % of normal EXCA, occurred at about 0.3 IU/ml (LMWH) 
enoxaparin concentration. The therapeutic anticoagulation, equivalent to about            
10-20 % of normal EXCA, occurred at about 0.6 IU/ml - 1 IU/ml (LMWH) enoxaparin 
concentration, i.e. the dosing of LMWH must be individualized according to patient 
need (prophylactic or therapeutic) and anticoagulant response as reflected by the 
EXCA. Target EXCA for prophylactic intention is 20-40 % of normal thrombin 
generation whereas for therapeutic intention and prophylactic anticoagulation in high-
risk patients (e.g. orthopaedic knee surgery) (Stief TW. 2007b) it is 10-20 % of normal 
thrombin generation.  
The mean approximate 50 % inhibitory concentration (IC50) of unfractionated heparin 
or low-molecular-weight-heparin (LMWH) enoxaparin in citrated plasma samples of 
normal healthy donors was 0.08 IU/ml, 0.14 IU/ml in EXCA respectively. 
0.01 IU/ml heparin or enoxaparin reduced normal thrombin generation in EXCA by 
about 10 % or 20 %, respectively. But 1 IU/ml (LMWH) enoxaparin concentration 
reduced the normal thrombin generation in EXCA to about 13 % of normal whereas at 
1 IU/ml heparin the normal thrombin generation was completely inhibited. 
This means that LMWH enoxaparin at 1 IU/ml concentration is a strongly therapeutic 
anticoagulant, unfractionated heparin at 0.01 IU/ml concentration is anticoagulantly too 
weak whereas at 1 IU/ml heparin there was almost no thrombin generation               
(toxic range). 
At anticoagulant concentrations in the range about 10 mIU/ml enoxaparin is more 
effective than the potential contact activator heparin (Stief TW. 2007a). 
Long-term anticoagulation with use nonphysiologic antiVit.K-anticoagulants 
(Phenprocoumon (Marcumar), Coumadin (Warfarin) and Acenocoumarol (Sintrom) 
derivatives) with target INR rang of 2-3 results in about 10 % of patients in severe 
bleeding or in thrombo-embolic complications (Olsson SB. 2005; Indredavik B. 2005; 
Cheung CM. 2005; Reynolds MW. 2004), i.e. an INR of 2-3 is in some patients too 
high and in others it is too low. This might be due to a lack of relationship between INR 
and the plasmatic serine proteases F2 and F10 (Sarode R. 2006). 25 % of patients 
treated with vitamin K epoxide reductase inhibitors develop intracranial hemorrhage by 
target INR rang less than 2.5 (Toyoda K. 2007; Rosand J. 2004; Lee SB. 2006). 
Therefore, it is suggested to replace vitamin k antagonists by LMWHs and to monitor 
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their efficiency via an ultra-specific thrombin generation assay, such as the EXCA 
(Stief TW. 2008c).  
The present data of study support the concept that the LMWH dosage of each 
individual patient should be adjusted with an ultra-specific thrombin generation assay. 
The present study demonstrates that unfractionated heparin at 0.1 mIU/ml concentration 
does not decrease thrombin generation in RECA-40; instead it even increased the 
thrombin generation in RECA-40 by about 20 % higher than that in unsupplemented 
plasma, whereas 0.1 mIU/ml enoxaparin significantly decreased thrombin generation in 
RECA-40 by about 30%- 60%. 
Polynegative sulphated glycosaminoglycans (SGAG) sized 15000 to 18000 Daltons 
activate antithrombin-3 (AT-3) and prekallikrein when compared with low molecular 
weight heparin enoxaparin sized 4500 Daltons that only activate AT-3 without any 
activated influence on prekallikrein, a trigger intrinsic pathway of hemostasis                
(Stief TW. 2007a), i. e. heparin at a temperature higher than 23 °C and lower than 37°C  
has a dual function: anticoagulant (through activation AT-3) and procoagulant (through 
activation prekallikrein into kallikrein).  
In ultra-low concentrations, the ability of UFH to activate prekallikrein is superior to its 
ability of AT-3 activation. Enoxaparin does not show this phenomenon, wherefore 
enoxaparin might be the clinically preferred drug to avoid these complications of 
heparin. It is suggested to monitor the correct dosage of enoxaparin for each individual 
patient (Fareed J. 1990; Dawes J. 1990) by innovative thrombin generation assays. In 
ultra-low concentrations, as e.g. occurring in the end of heparin infusion, heparin might 
dangerous especially for some susceptible patients. It is suggested to add enoxaparin to 
heparin at the end of heparin infusion with administration of enoxaparin, and to 
monitor the correct dosage of enoxaparin in each individual patient by specific 
thrombin generation assays. 
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